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Perturbation of iron distribution is observed inmany neurodegenerative disorders, including
Alzheimer’s and Parkinson’s disease, but the comprehension of the metal role in the
development and progression of such disorders is still very limited.The combination ofmore
powerful brain imaging techniques and faster genomic DNA sequencing procedures has
allowed the description of a set of genetic disorders characterized by a constant and often
early accumulation of iron in speciﬁc brain regions and the identiﬁcation of the associated
genes; these disorders are now collectively included in the category of neurodegeneration
with brain iron accumulation (NBIA). So far 10 different genetic forms have been described
but this number is likely to increase in short time. Two forms are linked to mutations in
genes directly involved in iron metabolism: neuroferritinopathy, associated to mutations in
the FTL gene and aceruloplasminemia, where the ceruloplasmin gene product is defective.
In the other forms the connection with iron metabolism is not evident at all and the genetic
data let infer the involvement of other pathways: Pank2, Pla2G6, C19orf12, COASY, and
FA2H genes seem to be related to lipid metabolism and to mitochondria functioning,
WDR45 and ATP13A2 genes are implicated in lysosomal and autophagosome activity,
while the C2orf37 gene encodes a nucleolar protein of unknown function. There is much
hope in the scientiﬁc community that the study of the NBIA forms may provide important
insight as to the link between brain iron metabolism and neurodegenerative mechanisms
and eventually pave the way for new therapeutic avenues also for the more common
neurodegenerative disorders. In this work, we will review the most recent ﬁndings in the
molecular mechanisms underlining the most common forms of NBIA and analyze their
possible link with brain iron metabolism.
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INTRODUCTION
The recent advance in magnetic resonance imaging (MRI) tech-
niques and the increased ability to identify causative genes led
to the recognition of a new group of disorders named neurode-
generation with brain iron accumulation (NBIA). It is a set of
degenerative extrapyramidal monogenic disorders with radiolog-
ical evidence of focal accumulation of iron in the brain, usually
in the basal ganglia (Yoshida et al., 1995; Gregory et al., 2009; Gre-
gory and Hayﬂick, 2011). They are characterized by early or late
onset, with the main symptoms associated to problems in the
movement, spasticity, and cognitive impairment. The diagnosis of
NBIA is made on the basis of the combination of representative
clinical features along with MRI evidence of iron accumulation
(Kruer and Boddaert, 2012). Imaging details can be so speciﬁc to
orient the successive genetic analysis required to include the dis-
ease in a genetically conﬁrmed category or in the idiopathic group,
that still represent about 30% of all cases (Dusek et al., 2013).
Different disorders were grouped under this category (Table 1):
neuroferritinopathy, aceruloplasminemia, pantothenate kinase-
associated neurodegeneration (PKAN), phospholipase 2, group
VI-associated neurodegeneration (PLAN), mitochondrial mem-
brane protein-associated neurodegeneration (MPAN), fatty acid
hydroxylase-associated neurodegeneration (FAHN), β-propeller
protein-associated neurodegeneration (BPAN), and two other
forms, the Kufor–Rakeb disease and the Woodhouse–Sakati syn-
drome, which are not always associated to brain iron accumula-
tion. Very recently a new form was identiﬁed. Exome sequencing
revealed the presence of recessive missense mutations in the
COASY gene, encoding coenzymeA (CoA) synthase, in oneNBIA-
affected subject and conﬁrmed in a second unrelated patient (Dusi
et al., 2014). The authors proposed COASY protein-associated
neurodegeneration (CoPAN) as the name to classify this disorder.
Themain characteristics of thedifferent types of geneticNBIA syn-
dromes are summarized in Table 1. They show variable incidence,
and, from an epidemiological point of view, it is also important
to note that these diseases are extremely rare and some are gener-
ally conﬁned to speciﬁc populations (Dusek and Schneider, 2012,
2013).
We are particularly interested in iron homeostasis and the
mechanisms underlining its accumulation in the brain. By this
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Table 1 | List of the neurodegeneration with brain iron accumulation disorders.
Human disorder Brain regions interested by iron
deposition
Symptomatology
Aceruloplasminemia Dentate nucleus, globus pallidus, putamen,
caudate
Diabetes, anemia, dementia, dystonia, dysarthria
Neuroferritinopathy; hereditary ferritinopathy;
NBIA type III
Dense ferritin-Fe spheroid inclusions in
dentate nuclei, globus pallidus, putamen,
caudate, thalamus, and red nuclei
Dementia, dystonia, dysarthria in some cases
cognitive decline
Pantothenate kinase-associated
neurodegeneration (PKAN, NBIA type I,
Hallervorden–Spatz syndrome)
Globus pallidus (eye of the tiger) Dystonia, with predominant oro-lingual-mandibular
involvement, and spasticity
Phospholipase 2, group VI-associated
neurodegeneration (PLAN, NBIA type II; INAD1;
Karak syndrome)
Globus pallidus and substantia nigra (in
<50% of patients)
Infantile neuroaxonal dystrophy: hypotonia, visual
disturbance, motor and mental retardation.
Atypical neuroaxonal dystrophy (late onset):
dystonia, dementia, and parkinsonism
Mitochondrial membrane protein-associated
neurodegeneration (MPAN)
Globus pallidus and substantia nigra Dysarthria, gait abnormalities, dystonia, and
parkinsonism
Fatty acid hydroxylase-associated
neurodegeneration (FAHN)
Globus pallidus and substantia nigra in some
patients
Dysarthria, gait abnormalities, dystonia, and
parkinsonism
COASY protein-associated neurodegeneration
(CoPAN)
Globus pallidus and substantia nigra Oro-mandibular dystonia with dysarthria and
parkinsonism, cognitive impairment
β-Propeller protein-associated neurodegeneration
(BPAN)
Globus pallidus and substantia nigra Parkinsonism, dystonia, dementia, and global
development delay
Kufor–Rakeb syndrome Globus pallidus and substantia nigra in few
cases
Dystonia and parkinsonism
Woodhouse–Sakati syndrome Globus pallidus and substantia nigra in few
cases
Dystonia and deafness
point of view, the genes so far associated with different NBIA
forms can be distinguished between those that code for proteins
directly involved in iron metabolism and those that encode pro-
teins responsible for other functions such as fatty acid metabolism
and lysosomal activity (Table 2). The proposal of hypotheses about
iron accumulation mechanisms may be relatively easy in the ﬁrst
case; while for the other type of defects it could represent a difﬁcult
challenge.
Here we will try to critically resume the main results obtained
from in vitro and in vivo studies of the pathogenicmolecularmech-
anisms with the aim to highlight the iron involvement in the NBIA
pathogenesis, which is still far to be clariﬁed, while for a compre-
hensive review of clinical symptoms, phenotype and how to make
a differential diagnosiswe refer to several recent papers appeared in
the literature (Kruer andBoddaert, 2012; Rouault, 2013; Schneider
et al., 2013).
NBIA CAUSED BY DEFECTS IN GENES CODING FOR
PROTEINS OF IRON METABOLISM
Until now, only two genes coding for iron proteins have been
identiﬁed as responsible of NBIA subtypes: the ceruloplasmin
gene (CP) causing aceruloplasminemia (Miyajima et al., 1987)
and the L-ferritin gene (FTL) altered in neuroferritinopathy (Cur-
tis et al., 2001). Defects in these genes lead to early deposits of
iron in the striatum, thalamus, globus pallidus (GP), dentate
nuclei, cortex, retina; the clinical symptoms typically mani-
fest in adulthood, suggesting that the brain possesses excellent
compensatory mechanisms to buffer the harmful action medi-
ated by iron. Neurologic manifestations include blepharospasm,
oro-lingual-mandibular dystonia, dysarthria, chorea, parkin-
sonism, ataxia, and cognitive decline (Dusek and Schneider,
2012).
ACERULOPLASMINEMIA
Aceruloplasminemia (MIM 604290) is an autosomal recessive
inherited disease. It was originally described by Miyajima in
a Japanese female in 1987 (Miyajima et al., 1987). Effectively,
it affects particularly the Japanese population with a preva-
lence of approximately 1 per 2,000,000 in non-consanguineous
marriages, while other 35 families have been described around
the world (Kono, 2013). The symptoms include neurologi-
cal signs with ﬁrst appearance in adulthood (fourth or ﬁfth
decade of life), usually preceded by diabetes mellitus, retinal
degeneration (Kono, 2012) and microcytic anemia, unresponsive
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Table 2 | Causative genes of the neurodegeneration with brain iron accumulation disorders.
Gene/disorder Function Cellular location Molecular process
Ceruloplasmin (Cp)/ aceruloplasminemia Cu-dependent ferroxidase Secreted – plasma membrane Iron metabolism
Ferritin light chain
(FTL)/ neuroferritinopathy
Iron storage Cytosol Iron metabolism
Pantothenate kinase-2 (PanK2)/PKAN Vitamin B5 phosphorylation Mitochondria Coenzyme A synthesis (fatty acid
metabolism)
Phospholipase A2, Group VI (PLA2G6;
iPLA2β)/PLAN
Hydrolysis of ester bonds at the
sn-2 position of phospholipids
Mitochondria and cytosol Membrane phospholipids turnover
C19orf12/MPAN Unknown Mitochondria Lipid metabolism?
Fatty acid 2-hydroxylase (FA2H)/FAHN Synthesis of 2-hydroxysphingolipids Endoplasmic reticulum Myelin synthesis
COASY/COPAN CoA synthase (4′-PP
adenyltransferase and
dephospho-CoA kinase)
Mitochondria and cytosol Coenzyme A synthesis (fatty acid
metabolism)
WDR45/BPAN Putative role in autophagy Autophagosome? Autophagy
ATP13A2; PARK9/ Kufor–Rakeb syndrome P-type ATPase – divalent cation
pump
Lysosome Lysosomal degradation – autophagy
C2orf37/Woodhouse–Sakati syndrome Unknown Nucleolus? Unknown
to treatment with iron, accompanied by undetectable serum
ceruloplasmin, high serum ferritin levels (from 3 to 40 times
the normal levels), and low levels of sideremia (Ogimoto et al.,
2011). MRI analysis of aceruloplasminemia patients reveals
abnormal low intensities in the liver as well as in the stria-
tum, thalamus, and dentate nucleus of the brain on T1 and
T2 weighted images, which are consistent with iron deposition
(Miyajima, 2003).
Up to now analysis of autopsies from six cases of acerulo-
plasminemia patients have been reported (Morita et al., 1995;
Yoshida et al., 1995; Gonzalez-Cuyar et al., 2008; Kaneko et al.,
2012). They showed severe destruction of the basal ganglia
and dentate nucleus, with considerable iron deposition in neu-
ronal and glial cells. In the majority of them the cerebral
cortex showed mild iron deposition in glial cells without neu-
ronal involvement, however in one case, in which the pathology
lasted for the longest time, iron overload was detected also in
the cerebral cortex, indicating that the neuropathologic process
in aceruloplasminemia worsened during the time and extended
beyond the basal ganglia to the cerebral cortex (Kaneko et al.,
2012). A sustained accumulation of iron occurs also in retina
and cerebellum other than in the pancreas and myocardium
(Kaneko et al., 2012). Iron deposition was detected in perivas-
cular areas, localizing to terminal astrocytic processes, especially
in the basal ganglia, which show neuronal loss and accumu-
lation of large iron-rich globular structures that appear to be
the remains of dead astrocytes (Gonzalez-Cuyar et al., 2008).
Accordingly, enlarged or deformed astrocytes and spheroid-like
globular structures are characteristic neuropathological ﬁndings
in aceruloplasminemia.
CP is a single-copy gene on chromosome 3, which contains
20 exons with a total length of about 65 kb (Patel et al., 2000),
and encodes ceruloplasmin (Cp). The genetic analysis of patients
affected by aceruloplasminemia revealed more than 40 distinct
causative mutations (Kono, 2013).
Cp is a glycoprotein of the α2-globulin fraction of the serum.
It is a multicopper ferroxidase, containing 95% of the copper in
the plasma. Its functional role is to facilitate iron export, medi-
ated by ferroportin, from cells. It oxidizes the Fe2+ to Fe3+ so
that the ferric iron can bind to transferrin present in the extra-
cellular environment. In central nervous system (CNS), Cp is
expressed as a glycosylphosphatidylinositol (GPI)-linked form in
the astrocytes (Patel et al., 2002). Its action is essential in this
cerebral cell type for which the Cp is the only existing ferrox-
idase (Jeong and David, 2003). In the absence of Cp activity,
the ferrous iron that enters the CNS cannot be oxidized and is
internalized in large amount, through transferrin-independent,
non-regulated pathway (Brissot et al., 2012). The excess import
of iron, associated to the export inability due to ferroportin
malfunctioning in the absence of Cp, leads to the remarkable
accumulation of iron within astrocytes observed in the pathol-
ogy. Thus it is reasonable to think that iron sequestration by
astrocytes may induce iron deﬁciency and death in neurons,
which are astrocytes-depended for iron acquisition (Jeong and
David, 2006). Other cells in the CNS, including oligodendro-
cytes, express hephestin as alternate ferroxidase (Wang et al., 2007)
and are not dependent on the action of Cp; this explains the
speciﬁcity of astrocytes and neuronal death. In brain tissues
and cerebral ﬂuid there is also evidence of a marked increase in
oxidative stress such as lipid peroxidation and protein carbony-
lation, in support to excess iron-toxicity (Kono and Miyajima,
2006).
The molecular pathogenesis of aceruloplasminemia was inves-
tigated by analysis of Cp mutants expressed in mammalian cell
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culture (Hellman et al., 2002; Kono et al., 2007, 2010; di Patti et al.,
2009) and by characterizing murine models (Harris et al., 1999;
Patel et al., 2002; Yamamoto et al., 2002).
The in vitro biological analysis of Cp mutants revealed three
different types of pathological mechanisms, all resulting in loss
of the protein ferroxidase activity. The protein structural modiﬁ-
cations induced by mutations can lead to: (i) retention of Cp in
the endoplasmic reticulum (ER), (ii) miss-incorporation of cop-
per into apoceruloplasmin, and (iii) impaired ferroxidase activity
(Hellman et al., 2002; Kono et al., 2007, 2010; di Patti et al., 2009).
All these events hinder iron export from the cell, leading to cellular
iron overload.
The in vivo experiments were performed on different mice
models obtaining variable results. The ﬁrst knockout mice gen-
erated on a C57BL/6J genetic background were described by
Harris et al. (1999). The mice showed increased iron content
with lipid peroxidation in the brain, but they did not suf-
fer of neurological symptoms; however, a more recent work
revealed that this CP-deﬁcient young adult mice showed an
anxiety phenotype, without discernable effects on learning and
memory or motor performance (Texel et al., 2012). The authors
determined that in contrast to peripheral tissues, iron levels
in the hippocampus were signiﬁcantly reduced in CP-KO mice
and, paradoxically, that the anxiety phenotype resulted from
reductions in the levels of iron, serotonin, and brain-derived
neurotrophic factor expression in the hippocampus (Texel et al.,
2012).
A second knockout mice model was developed with a differ-
ent strategy by Patel et al. (2002). Also in this case CP-null mice
showed increased iron deposition and lipid peroxidation in sev-
eral regions of the CNS, but, in addition, they showed deﬁcits in
motor coordination that were associated with a loss of brainstem
dopaminergic neurons. Astrocytes isolated from the CNS of these
CP-null mice were used to investigate the functional role of Cp
in CNS (Jeong and David, 2003). The authors assessed the 59Fe
inﬂux and efﬂux from astrocytes and concluded that GPI-Cp is
essential for iron efﬂux, while is not involved in regulating iron
inﬂux. Furthermore, they identiﬁed the co-localization of GPI-Cp
on the astrocyte cell surface with the divalent metal transporter
IREG1 (now renamed ferroportin) and deﬁned that the harmo-
nized actions of GPI-Cp and IREG1 is required for iron efﬂux from
neural cells. If disruption of this equilibrium occurs, it could lead
to iron accumulation in the CNS and neurodegeneration, high-
lighting the importance of Cp in maintaining iron homeostasis in
brain.
In 2002, Yamamoto described a third type of knock-
out obtained on C57BL/10 and BALB/c genetic background
(Yamamoto et al., 2002). The mice had hepatic iron overload
but no brain iron accumulation was detected. This murine
model was then also investigated for the age dependent expres-
sion of hephestin (Cui et al., 2009). The authors detected
regional difference in age-dependent hephestin expression and
concluded that hephestin may compensate for the loss of Cp
in a region-speciﬁc manner (Cui et al., 2009). These interest-
ing results might explain the evidence that adult CP-null mice
have increased iron deposition in the cerebellum and brain-
stem, while other regions (such as the caudate and putamen),
appeared to have normal iron levels (Patel et al., 2002). Unfor-
tunately, the latter brain regions show iron accumulation in
aceruloplasminemia patients, indicating the limit of this murine
model in recapitulating the aceruloplasminemia human pheno-
type.
The murine model that lacks the action of both Cp and
hephestin develops symptoms consistent with those shown by
aceruloplasminemia patients (Hahn et al., 2004; Schulz et al.,
2011). Together with iron accumulation in both gray and white
matter oligodendrocytes (Schulz et al., 2011) these mice also
showed macular degeneration, iron overload and increased oxida-
tive stress in the retina, (Hadziahmetovic et al., 2008). The use
of a chelating agent, such as oral deferiprone (DFP), was shown
to be protective against the increased oxidative stress and retinal
degeneration (Hadziahmetovic et al., 2011; Wolkow et al., 2012).
Despite the good results obtained in the mouse model, the use of
DFP on a patient resulted in a worsening of symptoms (Mariani
et al., 2004), while variable results ranging from mild ameliora-
tion to no effect on neurological symptoms were obtained in
patients treated with deferasirox (Skidmore et al., 2008; Roberti
Mdo et al., 2011). However iron-chelating therapy appeared
effective in reducing the hepatic and pancreatic iron overload
(Finkenstedt et al., 2010).
Thus, the cascadeof events leading toneuronal death remains to
be fully elucidated but the overall data strongly suggest that oxida-
tive stress, driven by heavy metal accumulation, represents the
primary cellular cytotoxic process, determining the neuronal dam-
age in affected brain regions. Nevertheless, it has been described
that some mutated forms of Cp can also accumulate in aggre-
gates and lead to death of astrocytes through an iron-independent
pathway (Kono et al., 2006).
NEUROFERRITINOPATHY
The Neuroferritinopathy (OMIM, 606159, also labeled as hered-
itary ferritinopathies or NBIA3) is a rare monogenic autosomal-
dominant progressive movement disorder caused by mutations
in the gene encoding the L chain of ferritin (FtL). Ferritin (Ft)
is the main protein iron storage from prokaryotes to mam-
mals and is characterized by a highly conserved structure that
consists of a virtually spherical shell with an internal cavity
that can accommodate up to 4500 iron atoms. In vertebrates
Ft consists of 24 subunits of two types, H and L, which are
assembled in different proportions (Arosio and Levi, 2010). The
three dimensional structure of the two chains is very similar:
a bundle of four parallel helices, with a long loop that con-
nects helix B and helix C, and a ﬁfth smaller helix called E,
at the C-terminus, which is directed toward the center of the
cavity. The H chain has a ferroxidase center, where the oxi-
dation of iron occur (Lawson et al., 1991), while the L chain
facilitates the mineralization of the iron in the cavity support-
ing the ferroxidase activity of the H chain (Levi et al., 1994),
thus the heteropolymer incorporates iron more efﬁciently than
homopolymers, both in vitro and in vivo (Santambrogio et al.,
1993).
The disease was initially described in members of an English
family (Curtis et al., 2001; Table 3), which carried the inser-
tion of an adenine in FTL gene, resulting in alteration of the
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Table 3 | Reported cases of neuroferritinopathy.
Origin Reference Mutations Symptomatology Serum ferritin (normal
range 15–250 μg/l)
Cumbrian region (UK) Curtis et al. (2001) 460–461 dupA Extrapyramidal dysfunction 4–16
Northwest of UK Wills et al. (2002) 460–461 dupA Extrapyramidal dysfunction including palatal
tremor and cognitive decline
60
North of UK (10 families) Crompton et al. (2002) 460–461 dupA Extrapyramidal dysfunction N.D.
France Chinnery et al. (2007) 460–461 dup A Dystonia, dysarthria, chorea, parkinsonism,
blepharospasm, cerebellar signs, and
mitochondrial respiratory chain defects
N.D.
Gypsy ancestry Maciel et al. (2005) 474>A; A96T Parkinsonism, ataxia, and corticospinal signs 16
France Vidal et al. (2004) 498–499 dupTC Tremor, cerebellar ataxia, parkinsonism and
pyramidal signs, behavioral disturbances,
cognitive dysfunction
N.D.
French Canadian and
Dutch ancestry
Mancuso et al. (2005) 442 dupC Dystonia, dysarthria, chorea, blepharospasm,
cerebellar signs, and mitochondrial respiratory
chain defects
14
France Devos et al. (2009) 458 dupA Dystonia, dysarthria, dysphagia ND
Japan Kubota et al. (2009) 442 dup4bp Chorea, tremor, dyskinesia, dysarthria,
dysphagia
46
Japan, Italy (de novo) Ohta et al. (2008), Storti
et al. (2013)
469–484 dup16nt Hypotonia, hyperextensibility, aphonia, and
cognitive impairment
5
C-terminus of the protein encoded both in terms of sequence
and of length (Curtis et al., 2001). To date, six other alter-
ations have been identiﬁed, all of them localized in exon
4 of the FTL gene. All the mutations alter the helix E of
the FtL and determine a change in the C-terminal part of
the protein (Figure 1). In addition, a missense mutation,
causing A96T substitution on helix C, it has been described
as causative of the disorder (Maciel et al., 2005). The aver-
age age of onset is 39 years and the main clinical mani-
festations are those that characterize the extrapyramidal dis-
orders. Despite all the mutations determine common man-
ifestations such as oro-buccal dyskinesia, chorea, and dys-
tonia, it seems that there may be subtle phenotypic varia-
tions between them in terms of age of onset, progression
of the disease, or the presence of cognitive deterioration
(Lehn et al., 2012).
In these patients, routine blood tests are usually normal, only
serum ferritin may be low (Table 3), while electrophysiologi-
cal analysis of the cerebrospinal ﬂuid did not show appreciable
differences (Lehn et al., 2012). Standard histochemical analy-
sis of muscle biopsies are usually normal, however, Chinnery
et al. (2007) found a signiﬁcant percentage of cytochrome c
oxidase-negative ﬁbers in two of nine patients analyzed, in
addition to isolated or combined defects of respiratory chain
complexes in ﬁve of six patients analyzed. Iron deposits in
the cerebellum, basal ganglia and motor cortex are visible by
MRI, either with traditional gradient echo sequences (T2∗)
or with susceptibility weighted imaging (Ohta and Takiyama,
2012). The neuropathological data available were obtained from
patients with c.442dupC (p.His148ProfsX33; Mancuso et al.,
2005), the c.460dupA (p.Arg154LysfsX27; Curtis et al., 2001) and
c.498dupTC (p.Phe167SerfsX26; Vidal et al., 2004). The exami-
nation of the brains of these patients showed mild cerebral and
cerebellar atrophy as well as cavitation of the putamen. The
main neuropathological ﬁndings were the presence of intracy-
toplasmic and intranuclear aggregates of Ft in the glial cells and
in some neuronal subtypes, deposits of iron, gliosis, and neu-
ronal death. Glial cells that contain aggregates were found mainly
in the caudate, putamen, and GP, and these areas also showed
the death of nerve cells and extracellular deposits of Ft. In the
cerebral cortex, aggregates were found in cells of the perineu-
ral and perivascular glia. The presence of aggregates in neurons
was clearly visible in the putamen, the GP, thalamus, in cerebellar
granule, and Purkinje cells (Curtis et al., 2001; Vidal et al., 2004;
Mancuso et al., 2005).
The aggregates appeared as homogeneous eosinophilic bod-
ies, that were stained with antibodies anti-FtL, anti-FtH or
against the mutated form of the FTL; inclusions contained both
Fe2+ and Fe3+, the presence of which was analyzed respec-
tively using Turnbull blue and Perls’ Prussian blue. Using the
transmission electron microscopy, nuclear aggregates appeared
as granules of about 100 Å, reminiscent of the structure of
Ft and occupy a large part of the nucleoplasm. The pres-
ence of aggregates was also reported in cells of other tissues
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FIGURE 1 | Pile up of the C-terminus amino acid sequences of
L-ferritin and the mutants causing neuroferritinopathy. All
mutations, localized in the exon 4 of FTL, are nucleotide insertions
that cause large alterations of the C-terminal region of the subunit.
This peptide portion forms the E-helix region, which is involved in
the formation of the hydrophobic channel of the ferritin shell.
Position of the A96T mutation is indicated by a blue arrow along
the C-helix.
such as skin, liver, kidney, and muscle (Vidal et al., 2004;
Mancuso et al., 2005).
Biochemical analysis of the isolated aggregates identiﬁed FtH,
FtL, and FtL variant as components, suggesting that the variant
form assembles in the ferritin heteropolymers (Vidal et al., 2004).
Extensive work has been done on variant recombinant proteins
with the attempt to deﬁne the structural alteration induced by
mutations (Baraibar et al., 2008, 2010; Luscieti et al., 2010). The
crystallization of the p.Phe167SerfsX26 homopolymer (Baraibar
et al., 2008, 2010; Luscieti et al., 2010) showed that the mutated
L chain overlaps exactly with the wild type chain up to glycine
157 while the downstream portion of the amino acids sequence
is not solvable, suggesting that the ﬁnal part of the chain is
unstructured (Baraibar et al., 2008, 2010; Luscieti et al., 2010).
This alteration of the C-terminal and the exposure of this part of
the chain determines a disorganization of the channel described
above with two main consequences: a reduced physical stability
of the protein due to the loss of stabilizing interactions along
the axis of symmetry and the formation of a wider and perme-
able quaternary channel. These alterations of the hydrophobic
channel in the heteropolymer occur also when only one of four
subunits, that make up the channel, is changed, thus indicat-
ing a dominant negative effect exerted by the mutant protein
(Luscieti et al., 2010). Muhoberac et al. (2011) conﬁrmed a greater
propensity of ferritin to precipitation induced by iron and a lower
functionality of the heteropolymer containing variant chains.
Recently, it has also been reported a greater propensity to oxida-
tion of the mutated chains, both in vitro and in vivo, stressing
that oxidative stress is a key component of the pathogenesis
(Baraibar et al., 2012).
Overexpression of neuroferritinopathy variants in cells led to
the proposal of a hypothetical pathogenetic pathway (Cozzi et al.,
2006, 2010). Stable transfection of the p.Arg154LysfsX27 in HeLa
cells revealed that themutant chain assembles in the Ft heteropoly-
mers, although in low proportion (on average less than four
subunits for polymer); its expression is associated with an increase
in the endogenous ferritin chains expression and a decrease in
the expression of transferrin receptor 1 (TfR1). In addition, an
increase of reactive oxygen species (ROS) production is evident
after treatment with H2O2 in comparison to control cells. The
polymer containing the mutated chains incorporates iron with
lower efﬁciency and is degraded much faster than the wild type
protein. This leads to an increased release of iron in the cytoplasm,
which stimulates the expression of the endogenous ferritin chains,
that assemble with the mutant one thus establishing a vicious cycle
(Cozzi et al., 2006; Figure 2). Similar data were obtained also with
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FIGURE 2 | Scheme of pathogenetic molecular mechanism of
neuroferritinopathy.The mutated peptide (green ellipse) assembles with the
H- (red ellipse) and L- (blue ellipse) subunits to form ferritin shell, which is
unable to incorporate iron properly. This leads to iron excess in the cytosol
(cytLIP), which induces iron-dependent ferritin translation, generating a
self-maintained vicious cycle, and at the same time stimulating ROS
production and oxidative damage. In long period this causes impairment of
the proteasome, ferritin aggregation, and cell death.
expression of p.Phe167SerfsX26 in neuroblastoma cell lines (Cozzi
et al., 2010). When compared to control cells, both variant lines
showed an increase of endogenous ferritins, an increase in the
LIP after treatment with iron and an enhanced production of
ROS after treatment with H2O2, accompanied by an intensiﬁca-
tion in protein ubiquitination. Both cell lines develop aggregates
positive for FtL and iron, which grow in number and size upon
iron supplementation, and a defect in the proteasomal activity,
which is rescued by treatment with iron chelator and antioxidant
agents (Cozzi et al., 2010). These data are conﬁrmed by the analysis
of ﬁbroblasts from a patient carrying the c.498dupTC mutation
(Barbeito et al., 2010). These cells show an altered management of
iron, an accumulation of ferritin and markers of oxidative stress
(Barbeito et al., 2010). In basal conditions, the patient’s ﬁbrob-
lasts show a signiﬁcant increase compared with control ﬁbroblasts
in the amount of total iron, while the LIP is not altered; the
expression of H-, L-, and mutated-L Ft is increased, while that
of TfR1 is decreased. Furthermore, also the binding capacity of
IRP to IRE is decreased. The whole phenotype is consistent with
an increase in the intracellular free iron. Even in these cells the
level of ROS is signiﬁcantly increased compared to that of controls
(Barbeito et al., 2010).
In vivo data were obtained on a mouse model expressing the
human cDNA of FTL with the mutation c.498dupTC. The expres-
sion of the transgene in the animal caused the formation of
nuclear and cytoplasmic aggregates of ferritin throughout the
CNS and in other organs (Vidal et al., 2008). The size and the
number of nuclear aggregates increase with the aging of the ani-
mal, as is the case for patients (Vidal et al., 2004). The model
shows a progressive neurological phenotype, a decreased mobil-
ity and a reduced life expectancy as well as an increase in the
amount of iron in the brain with altered levels of the associ-
ated proteins. In fact, in brain the expression of H- and L-Ft is
increased while TfR1 expression is decreased. The transgenic mice
also show an accumulation of oxidized DNA in the mitochon-
dria of the brain but no signiﬁcant damage to the nuclear DNA
(Deng et al., 2010) even if oxidative stress markers such as protein
carbonylation and lipid peroxidation are elevated (Barbeito et al.,
2009).
In conclusion, the overall data obtained by in vitro analysis
of protein suggest that the pathogenesis could be caused by a
reduction in ferritin iron storage capacity and by enhanced toxic-
ity associated with iron-induced ferritin aggregates, whereas data
on cellular models, conﬁrmed by the study on transgenic mouse
model, imply that the pathogenesis could bemostly related to iron-
dependent oxidative damage. Thus, time should be invested now
in the development of therapeutic agents aimed at blocking the
detrimental cascade of oxidative events. Some promising results
have been recently obtained in more common diseases, such as
Parkinson’s disease (Devos et al., 2014), and might be extended to
these cases.
NBIA CAUSED BY DEFECTS IN GENES CODING FOR
PROTEINS INVOLVED IN LIPID METABOLISM AND
MEMBRANE HOMEOSTASIS
PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION
Pantothenate kinase-associated neurodegeneration (PKAN or
NBIA type I) is the most frequent syndrome among NBIA dis-
orders and it was the ﬁrst one to be associated to mutations in a
speciﬁc gene, namely pantothenate kinase 2 (PanK2; Zhou et al.,
2001). It accounts for about 50%of allNBIA cases andmay present
in two distinct and age-dependent forms, the classic one with early
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onset and the atypical one, with later onset of the disease. The clas-
sic form usually manifests in the ﬁrst decade of life, more often
before the age of 6 years (Hayﬂick et al., 2003). Gait and postu-
ral difﬁculties are the most common symptoms often associated to
extrapyramidal features such as dystonia, dysarthria, and choreoa-
thetosis. Spasticity and hyperreﬂexia as well as retinopathy are
often present. The atypical form most commonly presents in the
second decade of life and its clinical features are less homogeneous,
with less severe extrapyramidal and pyramidal signs. Difﬁculties
with speech and psychiatric symptoms with cognitive decline are
often observed.
The MRI analysis is a fundamental step in the diagnostic pro-
cess given that the vast majority of the patients show a speciﬁc
pattern deﬁned as “eye of the tiger” at T2-weighted MR images. It
corresponds to bilateral areas of hypointensity in the medial GP
with central spots of hyperintensity (Hayﬂick et al., 2003). The
area of reduced signal is due to iron accumulation in the tissue,
as conﬁrmed by the histology (Kruer et al., 2011), whereas the
central hyperintense signal may be linked to the dramatic rarefac-
tion of the tissue and the microglial activation (Sethi et al., 1988;
Kruer et al., 2011). On the basis of MR data the iron content in the
GP of PKAN patients would be about twice as much that found
in controls (391 vs 177 μg/ml; Dezortova et al., 2012); the larger
proportion of it would be inside ferritin as antiferromagnetic crys-
tals, but a minor part would have different, not yet determined
characteristics and have ferrimagnetic properties.
According to a recent study performed on six genetically con-
ﬁrmed PKAN cases (Kruer et al., 2011), the pathology of the
disease was almost exclusively located in the CNS, and particularly
in the GP where a strong reduction of neurons and synapsis was
evident. This was accompanied by the presence of reactive astro-
cytes, of numerous large and granular spheroids, corresponding to
degenerating neurons, and of small andmore eosinophil spheroids
corresponding to swollen dystrophic axons. Iron accumulation
was evident in the GP already on hematoxylin–eosin stain, partic-
ularly in the formof perivascular hemosiderindeposits, sometimes
within macrophages. The Perl’s staining showed the presence of
iron within the GP of PKAN brain with an intensity signiﬁ-
cantly higher than that observed in control brain; the accumulated
metal was particularly evident in the cytoplasm of astrocytes,
but could also be detected in some neurons, and with a more
diffuse pattern in the neuropil. Ferritin staining partially over-
lapped with the Perl’s result and was signiﬁcantly increased in
astrocytes, with a granular pattern, and in the neuropil; in some
degenerating neurons the iron staining seemed to be more intense
than that of the storage protein, ferritin. This could be in line
with the suggestion of two types of iron in the GP of patients
proposed from the interpretation of MR data (Dezortova et al.,
2012). Overall there was no evident correlation between the
intensity of iron accumulation and other histological or clinical
features.
An interesting observation was the positive staining for ubiq-
uitin found both in many degenerating neurons and in residual
intact neurons present in theGP,possibly indicating the accumula-
tion of ubiquitinated proteins as an early event in the degenerative
process. Less consistent was the staining for tau or amyloid precur-
sor protein (APP) in these cells. The latter was instead particularly
evident in neuroaxonal spheroids. In contrast with previous stud-
ies performed on Hallervorden–Spatz cases without a genetic
conﬁrmation of the disease (Galvin et al., 2000; Neumann et al.,
2000; Wakabayashi et al., 2000), no Lewy bodies were detected,
thus challenging the interpretation of PKAN as a synucleinopathy.
Pantothenate kinase-associated neurodegeneration is an auto-
somal recessive syndrome (OMIM number 234200) associated to
mutation in the PanK2 gene. Mutations are usually missense, with
c.1561G > A (p.G521R) and c.1583C > T (p.T528M) being the
most common, but deletions, duplications, and exon splice site
variations have been identiﬁed (Hartig et al., 2006). The predicted
functional severity of the mutations seems to correlate with the
age of onset, but not with the loss of ambulation and the course
of the disease (Hartig et al., 2006).
Four PanK genes are present in the human genome, which
code for PanK enzymes. The different isoforms (PanK1a and b,
Pank2, Pank3, and Pank4) share a common C-terminal catalytic
domain of about 350 amino acidswith about 80% identity and dif-
fer for the N-terminal portion of the protein, which contributes to
determine their speciﬁc cellular localization and regulatory prop-
erties (Leonardi et al., 2005; Alfonso-Pecchio et al., 2012; Garcia
et al., 2012). PanK2 gene consists of six core exons and differ-
ent initiating exons; the transcript variant 1 (NM_153638) is
the most common (Polster et al., 2010) and code for a protein
of 570 amino acids, with a long N-terminal domain. Target-
ing signals within the N-terminal part of the protein drive it to
mitochondria, where two sequential proteolytic cleavages by the
mitochondrial processing peptidase lead to the mature, long-lived
and active protein, with a molecular mass of 48 kD (Kotzbauer
et al., 2005). The alternate use of a downstream CTG codon
for translation initiation was described, that would give rise to
a protein of 50.6 kD, always with a mitochondrial localization
(Zhou et al., 2001; Johnson et al., 2004). Other transcript vari-
ants are described, but they are predicted to code short, not
functional cytosolic proteins. Different approaches have shown
that the mature PanK2 protein resides within the mitochondrial
intermembrane space (Alfonso-Pecchio et al., 2012; Brunetti et al.,
2012). Interestingly, a recent analysis of PanK proteins cellular
compartmentalization (Alfonso-Pecchio et al., 2012) conﬁrmed a
preliminary observation by Hörtnagel et al. (2003) and showed a
nuclear localization for PanK2, with the identiﬁcation of nuclear
targeting and export signals driving the entry of the protein into
the nucleus and the subsequent exit for the ﬁnal trafﬁcking to
the mitochondria. The functional protein exists as a dimer. The
mouse PanK2 gene structure is the same of the human gene, yet
there are conﬂicting reports as to the cellular localization of the
murine protein, alternatively documented in the cytosol (Leonardi
et al., 2007b; Alfonso-Pecchio et al., 2012) or in the mitochondria
(Brunetti et al., 2012).
A full comprehension of the mechanism linking defects in
PanK2 functioning with the neurodegenerative process and iron
accumulation in the brain is lacking yet, even though very recent
data provided new perspectives, also by the therapeutic point of
view. To deﬁne the biological mechanism underpinning the devel-
opment of this disorder different aspects await for clariﬁcation. Is
the perturbation of CoA biosynthesis the main pathogenic trig-
ger or does PanK2 have other biological functions? What are the
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relevance and the speciﬁc role of Pank2 in CoA biosynthesis and
what is the nature of its relationship with the other isoforms of
the enzyme? What is the connection linking Pank2 activity and
iron metabolism? Why is the brain and particularly speciﬁc cere-
bral areas and neurons so vulnerable to the degenerative process?
Even though many of the previous questions remain unanswered,
much progress has been recently obtained by different approaches
ranging from biochemical in vitro studies to the use of cellular and
animal models of the disease.
The recognized function of Pank2 is to catalyze the ﬁrst
and limiting step of CoA biosynthesis, that is the phosphory-
lation of pantothenate (vitamin B5) to 4′-phosphopantothenate
(Figure 3). This was shown in vitro, in transfected cells, where the
increased catalytic activity was predominantly found inmitochon-
dria (Kotzbauer et al., 2005; Zhang et al., 2006b). The enzymatic
activity was inhibited by CoA (IC50 = 50 μM) and more strongly
by a CoA ester (IC50 = 1 μM). This block could be overcome by
palmitoylcarnitine, that works as a potent activator of PanK2 func-
tion (Leonardi et al., 2007a). This explain how Pank2 can function
in vivo with the physiological concentration of CoA and acyl-CoA
esters and suggests that the presence of enzyme within the mito-
chondria inner space could be important to sense the levels of
palmitoylcarnitine and modulate CoA biosynthesis according the
requirement for β-oxidation. Interestingly the in vitro analysis of
different PanK2 mutants showed that in many cases the cellular
localization, the enzymatic activity, and the regulatory proper-
ties are all maintained or only modestly affected (Kotzbauer et al.,
2005; Zhang et al., 2006a; Leonardi et al., 2007a). This is for
instance the case with the c.1583C > T (T528M) mutation that
occurs with high frequency in both early and late onset diseases.
Experiments performed with wild type and mutant hPank2 in the
fumble (fbl) ﬂy model (Wu et al., 2009b) partially questioned the
reliability of these in vitro enzymatic assays and showed a bet-
ter correlation between loss of Pank2 catalytic activity and rescue
potency. Nonetheless the alteration of PanK2 catalytic activitymay
not be the only cause of the neurodegenerative process and the
possibility of other yet unknown functions of the protein has to be
considered. As a matter of fact no deﬁnitive evidence is available
showing decreased level of CoA in human Pank2 deﬁcient cells or
tissues. Recently, the CoA levels in mice with the genetic deletion
of Pank2 alone or in combination with Pank1 (dKO) were ana-
lyzed; no decrease was detected in any tissue in adult Pank2-KO
mice, while a signiﬁcant reduction was found in the brain of dKO
pups (Garcia et al., 2012). The study suggests that the expression of
the other PanK isoforms as well as that of CoA-degrading enzyme
such as Nudt7 and Nudt19 may compensate for the absence of
Pank2 function. Whether this occurs also in the human brain is
not known.
FIGURE 3 | Schematic description of genes and biochemical pathways involved in different types of NBIA disorders.The biochemical pathways of lipid
metabolism and membrane/organelles (mitochondria) remodeling seem to play an important mechanistic role in many of the genetic NBIA disorders so far
identiﬁed.
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Even though the precise role of Pank2 in CoA biosynthesis
in not fully understood yet, the strong connection between this
metabolic pathway and neurodegenerative processes is conﬁrmed
by the recent identiﬁcation of mutations in COASY in two sub-
jects with clinical and MRI features of NBIA (Dusi et al., 2014).
COASY is a bifunctional enzyme with 4′-PP adenyltransferase
(PPAT) and dephospho-CoA kinase (DPCK) activities, catalyzing
the last two steps in the CoA biosynthesis. Interestingly, in contrast
to previous reports showing localization of COASY at the outer
mitochondrial membrane (Tahiliani and Neely, 1987; Zhyvoloup
et al., 2002), these authors found the enzyme in the mitochondrial
matrix, probably anchored to the inner membrane. In the light
of this ﬁnding the possibility of a CoA biosynthetic process inside
the mitochondria has to be further considered and may explain
the speciﬁcity of Pank2 in this metabolic pathway.
Relevant insight into the biological mechanism connecting
defects of Pank2 function, CoA metabolism and the neurode-
generative process came from the drosophila model of the disease.
Drosophila has only one PanK gene, fbl. It gives rise to different
transcripts; the longest one (Fbl/L) seems to code for a protein
of 512 amino acids with a mitochondrial localization, while the
other proteins are cytosolic (Wu et al., 2009b). Fbl1, a hypomor-
phic allele, is due to a P-element insertion near the fbl locus.
Fbl1 ﬂies show defects in mitosis, male and female sterility, loco-
motor dysfunction, neurodegeneration, and reduced life-span
(Afshar et al., 2001; Bosveld et al., 2008). The levels of CoA in
the mutant ﬂies are signiﬁcantly lower than in control animals
and they are also reduced in Drosophila S2 cells exposed to spe-
ciﬁc fbl silencing (Rana et al., 2010); in deﬁcient animals and cells,
mitochondria are severely affected, with damaged and ruptured
cristae and membranes, and oxidized proteins are signiﬁcantly
increased. The reduction of de novo CoA synthesis is also asso-
ciated with a marked decrease in the acetylation of histones and
tubulin (Siudeja et al., 2011), proteins that are involved in neu-
rodegenerative processes (Fischer et al., 2010). The restoration of
appropriate acetylation levels by use of HDAC inhibitors partially
corrected many aspects of the phenotype of Pank2/fbl-deﬁcient
cells, such as radiation sensitivity, climbing activity, and homozy-
gous exclusion rate. Furthermore, reduced CoA levels led to
hyperphosphorylation and inhibition of twinstar, the ﬂy homolog
of coﬁlin, an essential factor for actin remodeling (Siudeja et al.,
2012). These biochemical changes are mediated by pathways that
involve Cdi kinase and slingshot phosphatase activities and led to
morphological changes in cells and compromised the differenti-
ation and neurite formation capability of human neuroblastoma
cells exposed to retinoic acid. Of extreme relevance the fact that
the addiction of pantethine to the diet of the mutant ﬂies or
to the culture medium of Pank2/fbl-deﬁcient cells determined
the correction of many of the described biochemical and func-
tional features (Rana et al., 2010; Siudeja et al., 2011, 2012). The
metabolite is probably reduced to pantetheine, and then converted
to 4′-phosphopantetheine, an intermediate of the canonical de
novo biosynthesis pathway downstream of PanK2 function. This
piece of evidence reinforces and strengthen the direct connection
between CoA metabolism and the neurodegenerative process of
PKAN. Very recently an alternate drosophila model has been gen-
erated with exclusive suppression of fbl in tissues with circadian
clock cells, that is eyes, fat and speciﬁc neural cells (Pandey
et al., 2013). The phenotype of these ﬂies recapitulated aspects
observed in the ﬂb1 hypomorphic animals, with increased sen-
sitivity to oxidative stress, developmental lethality, and shorter
lifespan; the transcriptome analysis revealed features partially
overlapping with those observed in ﬂies exposed to paraquat, that
is in pro-oxidant conditions, but also a speciﬁc signature with
perturbed expression of genes involved in mitochondrial path-
ways, cytoskeleton assembly, cell surface receptor signaling, and
eye pigment biosynthesis, that could be particularly relevant in
the development of retinal degeneration. Altogether the analysis
conﬁrmed the relevance of mitochondria and oxidative stress in
the pathogenesis of the disease, but also indicated a wide range
of transcriptional effects induced by Pank2/Fbl defects and CoA
deﬁciency, that could explain phenotypes observed in different
models, such as those related to cytoskeleton function and pro-
tein acetylation (Siudeja et al., 2011, 2012) and to iron metabolism
(Poli et al., 2010).
The analysis of the mouse model of the disease was at ﬁrst
disappointing, but more recently it has provided new important
insight into the disease pathogenesis and possibly opened new
therapeutic perspectives. Pank2 null mice were obtained by Kuo
et al. (2005) and were followed for more than 1 year. When com-
pared to littermates they showed a 20% reduction in size and were
infertile because of a block in spermiogenesis, with absence of
elongated and mature spermatids in the testis. Over time they
showed a progressive retinal impairment with alteration of the
retinal layers with cones and rods. No sign of motor dysfunction
nor of iron deposition in the brain were evident, as assessed either
by MRI and by histochemistry, even after 16 months of age or
after backcrossing into the C57/BL6J strain. With the exception
of retinal degeneration, these features were conﬁrmed in another
knock out mouse (Garcia et al., 2012). Tissues, form the latter
model, were also investigated for CoA level, and no difference
was observed in comparison to age-match littermates. Interest-
ingly, these authors reported that the deletion of Pank2 resulted
to be lethal in the C57/BL6J strain. Brunetti et al. (2012, 2014)
further analyzed the Pank2−/− mice and found a profound alter-
ation of the mitochondria, both in cultured neurons and in the
CNS and peripheral nervous system (PNS); these organelles were
swollen with altered cristae and membrane potential and oxy-
gen consumption was signiﬁcantly reduced, albeit the function of
respiratory chain complexes appeared to be normal. This was in
perfected agreement with the observation of damaged mitochon-
dria in the fbl hypomorph ﬂy. When Pank2−/− mice were fed with
a ketogenic diet for 2 months, they developed clear signs of motor
and neurological impairment, with foot clasping, tail rigidity,
and dystonic limb positioning. The histology revealed the pres-
ence of cytoplasmic, eosinophilic, PAS-positive inclusions in some
neurons. The anti-ubiquitin staining decorated these inclusions
but also smaller granules in apparently intact neurons and larger
ones in degenerating neural cells. The electron microscopy analy-
sis conﬁrmed the presence of altered mitochondria in the basal
ganglia of Pank2−/− mice; the phenomenon was dramatically
worsened by exposure to the ketogenic diet. Damaged mitochon-
dria were also found in the murine muscle and in the same tissue
from a PKAN patient. All of these features were rescued when
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pantethine was added to the diet, thus conﬁrming the beneﬁ-
cial effect of the metabolite observed in the Drosophila PKAN
model and indicating a possible therapeutic approach for PKAN
patients.
The accumulation of iron in the GP is a constant feature of
PKAN patients but no explanation of the phenomenon is avail-
able and very little has been done to understand it, also because
the available animal models of the disease showed no sign of iron
accumulation. A possible interpretation of the phenomenon was
linked to the detection of increased glutathione–cysteine mixed
disulﬁde together with reduced cysteine deoxygenase activity in
the GP of PKAN patients (Perry et al., 1985). The accumulated
cysteine would chelate iron and induce an abnormal produc-
tion of ROS with consequent damage to lipids and neuronal
membranes. Two works have studied cellular models to inves-
tigate possible biochemical mechanisms linking CoA and iron
metabolism. Speciﬁc siRNA silencing of Pank2 in different human
cell lines induced a mark reduction in cell proliferation together
with unexpected signs of iron deﬁciency, with decrease of Ft
and increase of TfR1 and free protoporphyrin levels (Poli et al.,
2010). The amount of aconitase, an iron-dependent enzyme,
was also reduced, both in the cytosol and in the mitochondria.
Interestingly, the reduced level of Pank2 was associated to a
remarkable increase of ferroportin expression, the sole cellu-
lar iron exporter, thus suggesting a possible linkage between
Pank2 function and iron transport to the brain. The oxidative
status and the response to iron supplementation were analyzed
in ﬁbroblasts from three PKAN patients and controls (Cam-
panella et al., 2012). Sign of oxidative stress were detected in
cells from patients already in basal conditions, and ROS produc-
tion was increased in these cells after exposure to iron. Under
these conditions the ﬁbroblasts from PKAN patients were not
able to modulate the binding of IRP1 to mRNA, which in turn
resulted in defect in the regulation of ferritin and TfR1 and in
higher amount of intracellular free iron (LIP; Figure 4). The
data suggest that the increased production of ROS associated
to Pank2 defects can perturb IRP1 activity and the control of
LIP, thus generating the condition for further ROS production
in a vicious cycle that could be extremely detrimental for neu-
rons. Even though the biological and clinical meaning of iron
accumulation in the brain of patients remains elusive, the admin-
istration of DFP, an iron chelating agent had beneﬁcial effects
and apparently reduced brain iron levels in two cases of idio-
pathic, adult-onset NBIA (Forni et al., 2008; Kwiatkowski et al.,
FIGURE 4 | Schematic representation of alteration of iron homeostasis
control in PKAN fibroblasts.The scheme shows the different structural
conformations of IRP1 (Apo, Fe–S, and mRNA-bound) in basal condition and
after iron addition, in control (A) and in PKAN (B) cells. In basal condition, the
amount of the regulatory functional form (mRNA-bound IRP1) is lower in
PKAN than in controls ﬁbroblasts. Controls cells respond to iron addition,
reducing the amount of mRNA-bound IRP1 and leading to up-regulation of
ferritin (Ft) and down-regulation of transferrin receptor 1 (TfR1). This does not
occur in PKAN cells where the levels of Ft andTfR1 do not change allowing
free iron increase.
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2012). More recently two clinical trials have tested the thera-
peutic potential of DFP; while the reduction of iron in the GP
was consistent, the clinical beneﬁt was absent in one case (Zorzi
et al., 2011) and only partial in the other one (Abbruzzese et al.,
2011). A study on a larger cohort of patients and for longer time
is undergoing (http://clinicaltrials.gov/ct2/show/study/NCT017
41532).
PHOSPHOLIPASE 2, GROUP VI-ASSOCIATED NEURODEGENERATION
PLA2G6-associated neurodegeneration (PLAN) is the second core
NBIA syndrome (NBIA type II, OMIM 256600 and 610217) and
is associated to mutations in the PLA2G6 gene (Morgan et al.,
2006). It can have two different age-related presentations, infantile
neuroaxonal dystrophy (classic INAD) and atypical neuroaxonal
dystrophy (atypical NAD). The former has an early onset presen-
tation, usually with psychomotor regression and within 3 years
of age and has a rapid progression, with neurological deteriora-
tion leading to loss of ambulation, four limb spasticity, truncal
hypotonia, cerebellar ataxia, optic nerve atrophy. The atypical
form has a later onset and a less homogeneous presentation with
gait problems, ataxia or speech difﬁculties being the most com-
mon symptoms (Gregory et al., 2008). Dystonia and dysarthria
together with neuropsychiatric features and visual defects charac-
terize the progression of the disease that usually allows a longer
life span than INAD. Rare forms of PLA2G6-associated dystonia-
parkinsonism have been also identiﬁed, characterized by sub
acute onset in early adulthood, frequently with neuropsychiatric
changes and gait disturbance. The patients then develop dystonia
and parkinsonism that may be accompanied by rapid cognitive
decline.
In INAD patients the MRI consistently show cerebellar cortical
atrophy often associated with signs of gliosis (Farina et al., 1999;
Kurian et al., 2008; McNeill et al., 2008). The accumulation of iron
is not a constant feature in patients. The metal deposition can be
detected in theGP, substantia nigra, and dentate nuclei and usually
increaseswithdisease progression. Changes in theposterior corpus
callosum and in the cerebral white matter are present. Promi-
nent brain iron accumulation eventually with cerebellar atrophy
can be the main neuroradiological sign in atypical INAD whereas
non-speciﬁc changes such as cerebral atrophy are reported for
individuals with PLA2G6-related dystonia-parkinsonism (Kurian
and Hayﬂick, 2013).
InPLA2G6-associatedneurodegenerationpathological changes
are widely distributed throughout the CNS. Cerebral atrophy and
sclerosis, with loss of neurons and gliosis, accumulation of lipid
and degeneration of the optic pathway are evident (Cowen and
Olmstead, 1963; Gregory et al., 2008). Depletion of cerebellar
granular and Purkinje cells can be present. Numerous axonal
swelling and spheroid bodies containing complex network of
tubulovesicular membranes are usually detected in the CNS (Itoh
et al., 1993; Gregory et al., 2008; Paisán-Ruiz et al., 2012). They are
30–100μmin size and can be often stainedwith antineuroﬁlament
antibodies. Less consistent is the sameobservation inbiopsies form
skin, peripheral nerves, muscle and conjunctiva of INAD patients
(Kurian et al., 2008). The analyses of brains form individuals with
genetically proven PLAN (Gregory et al., 2008; Paisán-Ruiz et al.,
2012) documented the presence of diffuse synuclein-positive Lewy
pathology, particularly evident in the neocortex. In some cases
there was evidence of tau pathology, either as threads in the den-
drites and axons or as neuroﬁbrillary tangles in neural bodies.
This suggests a close relationship between PLAN and Parkinson’s
disease.
Phospholipase 2, group VI-associated neurodegeneration is an
autosomal recessive disease linked to mutations in PLA2G6 gene
(Morgan et al., 2006). To date different types of sequence varia-
tions have been documented, including non-sense and missense
mutations, small exons deletions, splice-site, and copy number
variations (Morgan et al., 2006; Wu et al., 2009a; Crompton et al.,
2010). Even though no clear genotype/phenotype correlation
exists, the early onset and more aggressive forms are associ-
ated with two null mutations, while the atypical presentation
is more common in individuals carrying missense mutations.
The dystonia-parkinsonism type is associated with mutation not
affecting the catalytic domain of the enzyme (Engel et al., 2010).
The PLA2G6 gene maps to chromosome 22q13.1 and con-
tains 19 exons. Multiple transcript variants probably results
from alternative splicing and are expressed at variable levels in
most tissues. The two major isoforms (iPLA2β/iPLA2-VIA-1 and
iPLA2γ/iPLA2-VIA-2) are quite similar and differ because of a
lower number of ankyrin domains and a prolin-rich insertion at
the N-terminus of the type 2 protein. They are both catalytically
active and have a nucleotide binding-domain, a classical GSXSG
lipase consensus sequence and a calmodulin-binding site at the
C-terminus (Figure 5). The shorter isoforms (Ank-1 and Ank-2)
lack the catalytic domain and the enzymatic activity. The active
enzyme is a tetramer (Ackermann et al., 1994), probably enabled
by interaction among ankyrin repeats. It is thus possible that
the shorter inactive forms may act as dominant negative regula-
tors/inhibitors as shown by co-transfection experiments (Larsson
et al., 1998). The gene is ubiquitously expressed but seems to
have a particularly relevant role in the CNS. It can be found in
all regions of the mammalian brain and its activity is the most
prominent among PLA2s in the rat brain (Yang et al., 1999; Bal-
boa et al., 2002). The protein is usually considered to reside in
the cytosol, but translocation to membrane compartments has
FIGURE 5 | Schematic representation of the different iPLA2-VIA
isoforms. Group VI-1 is characterized by the presence of eight ankyrin
repeats (red circles), a glycine-rich, nucleotide-binding motif (G), a
consensus lipase motif (GXSXG), and a calmodulin binding motif (C). Group
VI-2 has the insertion of a proline-rich motif (P) in place of the eighth ankyrin
repeat. Group VI-3 has a truncated COOH-terminus but conserve the lipase
motif while the ankyrin-1 and -2 lack the active site and are non-functional.
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been documented as well as localization in the mitochondria
(Williams and Gottlieb, 2002; Seleznev et al., 2006); the latter
would be an important feature shared by different proteins coded
by genes associated to forms of NBIA and would point to mito-
chondria as central actors in the development of such disorders.
iPLA2β catalyzes the hydrolysis of ester bonds at the sn-2 posi-
tion of glycerophospholipids, thus releasing free fatty acids and
lysophospholipids (Balsinde and Dennis, 1997; Tang et al., 1997;
Burke and Dennis, 2009; Figure 5); the thioester bond in acyl-
CoAs is also a substrate of the enzyme that, in contrast to many
other members of the PLA2 family, is active in the absence of
calcium. The best recognized function of the enzyme is the home-
ostatic regulation of membranes topology, by modulating fatty
acids recycling and phospholipids amount in the membranes
(Balsinde and Dennis, 1997; Winstead et al., 2000); more recently
the protein has been implicated in a variety of other cellular pro-
cesses associated to the generation of arachidonic acid (AA; Green
et al., 2008) a precursor of eicosanoids such as prostaglandins
and leukotrienes, and lipid second messengers; the involvement
in cell signaling processes is well documented by the role played
in the control of cells proliferation (Balboa et al., 2008; Hooks
and Cummings, 2008), apoptosis (Shinzawa and Tsujimoto, 2003;
Pérez et al., 2006), insulin secretion (Zhang et al., 2006a), and
store regulated-calcium inﬂux (Smani et al., 2004; Strokin et al.,
2012).
The direct connection between defects in iPLA2β and the
development of the neurodegenerative process is not understood
yet. On the basis of the relevant role of the enzyme in control-
ling membrane phospholipid turnover and mass it is possible to
speculate that perturbation of membrane lipid homeostasis may
lead to the structure abnormalities and the axonal pathology that
characterizes the disease. This is probably an important but par-
tial aspect in the pathogenesis and further studies are needed to
understand the relevance of phospholipid metabolism and iPLA2
functioning in the brain and their involvement in PLAN and
other neurodegenerative disease. In contrast to PKAN, mam-
malian animal disease modeling has been successful for PLAN
and important advancement should come from the analysis of
the existing mouse models. PLA2G6 knock out mice are less fer-
tile because of spermatozoa malfunctioning and show defects
in pancreatic β-islet activity (Bao et al., 2004; Shinzawa et al.,
2008). More importantly, they developed a progressive neurologic
phenotype, with gait disturbances, defects in balance and climb-
ing, poor performance at the rotarod and the hanging grip test
(Malik et al., 2008; Shinzawa et al., 2008). The motor impairment
was evident at about 1 year of age, worsened with age and was
associated with a shorter lifespan (Shinzawa et al., 2008).The neu-
ropathological assessment revealed features strikingly similar to
those documented in INAD patients with numerous spheroids
and vacuoles affecting axons and the neuropil throughout the
brain and the PNS (sciatic nerve, mesenteric and celiac gan-
glia); these structures were often highlighted by the staining with
anti-ubiquitin antibody and sometimes were also positive for α-
synuclein; they often contained PAS-positive granules. Neither
Lewy bodies nor iron accumulation were evident in the brain of
PLAG26−/− mice. The ultrastructural examination evidenced a
frequent presence of tubulovesicular structures, vacuoles, dense
granules, and amorphous material in the spheroids. A very similar
phenotype was also observed other mouse models, either express-
ing a non-functional protein with an amino acid substitution
in the ankyrin repeat domain (Wada et al., 2009) or expressing
very low level of PLA2G6 transcript because of a viral insertion
upstream of the start codon (Strokin et al., 2012). In these mice
the motor impairment was already evident at 2 months of age
and progressively worsened. The mice died between 18 and 24
weeks of age. The pathology was characterized by the presence
of numerous spheroids, very similar to those observed in INAD
and containing tubulovesicular structures, vesicles, mitochondria,
and amorphous material; they were distributed both in CNS and
PNS,with particular involvement of the gracile and cuneate nuclei
of the brainstem (Wada et al., 2009). Iron accumulation was not
investigated in these mice. The striking temporal difference in the
manifestation of the phenotype among different mouse models
is not explained and raises the question whether the presence of
the mutant protein may contribute to the development of the dis-
ease. Important information regarding the possible pathogenic
pathway underpinning the disease have been recently provided
by Beck et al. (2011), who performed an in depth morphological
and biochemical analysis of the spinal cords and sciatic nerves of
PLA2G6−/− mice at 15 (presymptomatic stage), 56 (early clini-
cal stage), and 100 weeks (late clinical stage) of age. The presence
of PAS-positive granules in the perinuclear space and proximal
axons of neurons was the earliest abnormality detected in KO
mice. The granules were decorated with antibodies for TOM20, a
marker of the inner mitochondrial membrane. The ultrastructure
analysis revealed that these granules were remnants of mitochon-
dria ﬁlled with dense granules. At later stages swollen axons ﬁlled
with granules and vacuoles appeared and progressively increased
in number with age; many collapsed mitochondrial remnants
as well as abnormal mitochondria with branched and tubular
cristae and tubulovesicular structures were observed within the
swollen axons, where perturbation of the axonal cytoskeleton
was also evident. The plasma membranes at axon terminals were
also degenerated. The lipid content of these tissues was analyzed
by liquid chromatography/electron spray ionization tandem mass
spectrometry and by imaging mass spectrometry. A severe pertur-
bation in the relative amount of different types of phospholipids
was documented, with increase of the phosphatidylcholine con-
taining AA and docosahexaenoic acid (DHA), decrease of other
phosphatidylcholines and increase of phosphatidylethanolamines
and cardiolipins. Altogether these data suggest that the absence of
iPLA2β enzymatic activity may lead to an insufﬁcient remodeling
of the presynaptic and the mitochondrial inner membranes with
abnormal accumulation of DHA- and AA-containing phospho-
lipids; these perturbation would cause a progressive degeneration
of mitochondria and plasma membranes at synaptic terminals,
associated to alteration of the cytoskeleton, and ultimately deter-
mining the formation of tubulovesicular structures and swollen
axons, the main pathological features of INAD. Given the multi-
faceted role of iPLA2β in the cells, the existenceof parallel pathways
has to be taken into account, as demonstrated by the disturbance
in Ca++ signaling observed in astrocytes derived from two dif-
ferent mouse models of INAD (Strokin et al., 2012). Exposure of
astrocytes from mutant mouse strains to ATP revealed a shorter
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duration of Ca++ responses, associated to reduced capacita-
tive Ca++ entry. Similar results were obtained when wild type
cells were exposed to a chemical inhibitor of iPLA2β. Defects
in Ca++ responses could affect the neuron–astrocyte commu-
nication and potentially contribute to the development of the
disease.
As to the role of iron in PLAN development no studies and data
are available. In contrast to PKAN, the presence of iron is not a
constant feature of PLAN patients; furthermore, even though the
available animal models show a pathology remarkably similar to
that observed in patients, they apparently do not show evidence
of iron accumulation in the brain. Noteworthy, the analyses were
usually limited to the histological detection by the Perls’ stain-
ing. Altogether it may well be that the metal has not a relevant
role in PLAN pathogenesis, but more careful studies could pro-
vide important information as to the possible connection between
lipid and membrane homeostasis and iron metabolism in the
brain.
FATTY ACID HYDROXYLASE-ASSOCIATED NEURODEGENERATION
Most of the cases of NBIA are associated to mutations in PanK2
and in PLA2G6 genes, but many other NBIA genes have been
recently identiﬁed (Table 1). Interestingly the relevance of lipid
metabolism and membrane remodeling is further highlighted by
the association of mutations in the gene coding for the fatty acid-
2-hydroxylase (FA2H) enzyme (Kruer et al., 2010) with another
rare form of NBIA, named FAHN. The same gene is also involved
in hereditary spastic paraplegia SPG35 (Dick et al., 2010) and in
leukodystrophy (Edvardson et al., 2008). The clinical phenotype is
quite similar to that of PLAN with spasticity, dystonia, ataxia and
oculomotor disturbances. The MRI shows bilateral hypointensity
in theGP and in SN, related to iron accumulation, cortical atrophy,
and white matter lesions. The enzyme catalyzes the hydroxylation
of fatty acids in sphingolipids, essential constituents of myelin
sheaths (Figure 3). The relevance of this metabolic pathway for
axonal functioning and maintenance is evidenced by the pheno-
type of FA2H−/− mice, showing evident signs of demyelination
with axonal enlargement and loss in the CNS (Zöller et al., 2008;
Potter et al., 2011).
MITOCHONDRIAL MEMBRANE PROTEIN-ASSOCIATED
NEURODEGENERATION
Mutations in the C19orf12 gene are now associated with MPAN,
an autosomal recessive disorder that represents between 5 and
30% of NBIA cases (Hartig et al., 2011; Panteghini et al., 2012;
Hogarth et al., 2013). The evaluation of the genetically conﬁrmed
cases of MPAN allowed the identiﬁcation of a distinctive clinical
phenotype characterized by pyramidal and extrapyramidal signs,
cognitive decline, neuropsychiatric changes, optic atrophy, and
upper and lower motor neuron signs (Hartig et al., 2011; Hoga-
rth et al., 2013). Great variability is present both in disease onset
(between 3 and 30 years) and progression. Gait instability or
visual impairment are often the initial symptoms, then followed
by muscular weakness and atrophy, dystonia, and dysarthria.
Almost constant is the cognitive decline leading to dementia as
well as the appearance of neuropsychiatric modiﬁcations. Brain
iron accumulation is the most signiﬁcant sign at MRI. It usually
involves both the GP and the substantia nigra; it can be accom-
panied by cortical and cerebellar atrophy. The neuropathologic
assessment has been performed in two cases, with very similar
results and evidence of iron accumulation, axonal spheroids, tau
and Lewy pathology that affected the basal ganglia, the archicor-
tex, the neocortex, and the spinal cord. Iron was evident in
the GP and the substantia nigra, inside neurons, astrocytes and
macrophages with perivascular localization and associated with
neuronal loss and gliosis. Numerous eosinophilic axonal spheroids
were evident and were strongly immunoreactive for ubiquitin,
and less positive for tau or APP staining. Extremely remark-
able was the Lewy pathology with the presence of Lewy neurites
and Lewy bodies positive for α-synuclein staining in many brain
regions. In one case the overall burden was greater than that
observed in cases of sporadic Lewy body disease (Hogarth et al.,
2013). More recently mutations in C19orf12 gene have been
linked to cases of hereditary spastic paraplegia type 43 (Landouré
et al., 2013) and pallido-pyramidal syndrome (Kruer et al., 2014),
thus extending the clinical spectrum associated to C19orf12 gene
variants.
The C19orf 12 gene consists of three exons and codes
for two alternative mRNA isoforms (NM_001031726.3 and
NM_031448.4) and proteins that differ for the presence of a stretch
of 11 amino acids at the N-terminus of the longer form. Differ-
ent types of mutation have been identiﬁed and many of them
lead to truncated, non-functional proteins. Among the missense
mutation, the c.32C > T is the most common and affects tyro-
sine 11, exclusively present in the longer form. The protein has
a long hydrophobic domain (amino acid residues 42–75) that
could represent a transmembrane region; the presence of two
prolines in the middle of the domain suggests the possibility of
an hairpin structure. The longer form is localized in the mito-
chondria (Hartig et al., 2011) and possibly in the ER (Landouré
et al., 2013); its expression level is more signiﬁcant in the brain,
in blood cells and adipocytes and it appears to be co-regulated
with genes involved in fatty acid biogenesis and valine, leucine,
isoleucine degradation, that indicates a connection with CoA
and lipid metabolism and mitochondria. No other information
is available to explain the connection between the protein func-
tion, the neurodegenerative process, and iron accumulation in the
brain, but very recently a Drosophila model with impaired expres-
sion of the two orthologs of human C19orf12 was obtained (Iuso
et al., 2014); those ﬂies showed reduced life span and climbing
activity, signs of neurodegeneration (vacuoles) but not of iron
accumulation (negative Prussian blue staining). The model will
be an important tool to explore the mechanisms underlining the
disorder.
OTHER FORMS OF NBIA
β-PROPELLER PROTEIN-ASSOCIATED NEURODEGENERATION
Very recently a subset of NBIA cases with homogenous clini-
cal phenotype and disease history (known as SENDA) has been
linked to mutations in the WDR45 gene (Haack et al., 2012; Saitsu
et al., 2013) and is now identiﬁed as BPAN. The clinical pattern is
characterized by global developmental delay and intellectual deﬁ-
ciency in early childhood then followed by further neurological
and cognitive regression in late adolescence or early adulthood,
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with parkinsonism, dystonia, and sometimes ocular defects and
sleep perturbation (Hayﬂick et al., 2013). At the time of the clin-
ical deterioration the MRI shows clear sign of iron accumulation
involving the SN and the GP. A common and distinctive fea-
ture on T1-weighted-imaging is the presence of a thin line of
hypointensity in the SN and cerebral peduncles, surrounded by
a hyperintense halo. Cerebral and sometime cerebellar atrophy
are present. The pathology from a single postmortem sample is
available (Hayﬂick et al., 2013) and showed evident iron accu-
mulation in the SN and to a lesser extent in the GP. This was
associated with the presence of axonal spheroids, gliosis and neu-
ronal loss. In the cerebellum there was a signiﬁcant reduction
of Purkinje cells. Neuroﬁbrillary tangles were present in differ-
ent brain regions, while no positivity for α-synuclein or APP
deposition was evident. BPAN is due to “de novo” mutations in
the WDR45 gene causing loss of function of the encoded pro-
tein; even though the gene is at the chromosome X, males and
females present the same clinical phenotype, which seems to
be due to somatic mosaicism or skewing of the X chromosome
inactivation (Haack et al., 2012). The WDR45 gene codes for a
protein (WIPI4) with a seven-bladed beta-propeller structure and
a phosphoinositide-binding motif for membrane interaction. It
belongs to the large family of WD40 repeat protein and is one
of the four mammalian homologs of yeast Atg18, an important
regulator of autophagy. Its involvement in autophagy has been
documented in yeast and mammalian cells (Figure 3), where it
interacts with ATG2 (Behrends et al., 2010), and in C. elegans,
where its deletion leads to accumulation of early autophago-
some (Lu et al., 2011). The protein amount is clearly reduced in
lymphoblast cells from BPAN patients and the autophagosome
formation is hindered at an early stage as shown by the accu-
mulation of LC3-II protein and its co-localization with ATG9a in
enlarged membrane structures (Saitsu et al., 2013). Even though
the relevance of the autophagy process in neurons and brain is
well documented, this disorder represents the ﬁrst direct link
between the autophagy machinery and neurodegeneration; it
will be of great interest to analyze the correlation with iron
homeostasis.
KUFOR–RAKEB SYNDROME
Also Kufor–Rakeb disease (KRS; OMIM 606693) is due to muta-
tions in a gene, namely ATP13A2, encoding a protein involved
in degradation processes. It is a rare autosomal disorder also
identiﬁed as Parkinson’s disease 9 and characterized by early-
onset parkinsonism, pyramidal signs, altered eye movements and
dementia. Some cases show signs of bilateral iron deposition in the
basal ganglia at the MRI, and they can be added to the group of
NBIA (Schneider et al., 2010). Mutation in the same gene are also
linked to cases of neuronal ceroid lipofuscinosis (NCL; Bras et al.,
2012). Indeed, the accumulation of lipofuscin andα-synucleinwas
also observed in ATP13A2-null mice (Schultheis et al., 2013).
The gene codes for a type 5 P-type ATPase, a cation pump
located in the lysosome whose function is not deﬁned yet.
Different studies in patients’ primary cells and in ATP13A2 null-
mice have investigated the function of the protein suggesting its
involvement in divalent cation handling, and lysosomal and mito-
chondrial functioning. The analysis of ﬁbroblasts from patients
carrying mutations in the ATP13A2 gene evidenced severe per-
turbations of lysosomal function, with impaired degradation
of substrates, reduced processing of lysosomal enzymes and
decreased autophagosomes clearance (Dehay et al., 2012; Usen-
ovic et al., 2012). The downregulation of ATP13A2 expression
in dopaminergic neurons or mouse primary cortical neurons
induced the same phenotype and cell death, together with α-
synuclein accumulation. Fibroblast from patients’ also showed
impaired maintenance of mitochondria, with network frag-
mentation, mitochondrial DNA alterations, reduced membrane
potential, and ATP production (Grünewald et al., 2012). Similarly,
silencing of ATP13A2 in rat primary cortical neurons induced
mitochondrial fragmentation either in basal condition or after
exposure to cadmium (Ramonet et al., 2012). It is probable that
these perturbations in organelle function and structure are linked
to altered cation transport and/or homeostasis. Lysosomal Zn++
sequestration was shown to be impaired in patients’ ﬁbroblasts
(Tsunemi and Krainc, 2013) and olfactory neurosphere cultures
(Park et al., 2014) and this was associated with increased expres-
sion and accumulation of α-synuclein, elevation of ROS levels,
ATP depletion and mitochondrial dysfunction, leading to cell
death. The overexpression of ATP13A2 or Zn++ chelation could
block Zn++ toxicity (Park et al., 2014). Furthermore KRS mutants
were not able to protect cells form Mn++-dependent cytotoxic-
ity (Tan et al., 2011). Even though no evidence suggests a direct
role of the P-type ATPase in iron intracellular handling, the
lysosomes, and acidic endosomes are fundamental for iron home-
ostasis and perturbation of their functioning may be linked to the
accumulation of the metal observed in the brain of some KRS
patients.
CONCLUSIONS AND FUTURE PERSPECTIVES
While each of these NBIA types is associated to mutations in dif-
ferent genes, it is possible to underline common features that may
point to shared pathogenic pathways. Aceruloplasminemia and
neuroferritinopathy have in common iron mis-handling, which is
the primer trigger of cellular oxidative damage, while the involve-
ment of lipid metabolism and mitochondria is evident in many of
the other diseases. It is clear for PKAN and PLAN in which mito-
chondrial network fragmentation, altered cristae and structural
and functional abnormalities are well documented (Rana et al.,
2010; Beck et al., 2011; Brunetti et al., 2012) and are probably
linked to perturbation in the synthesis (PanK2) or the remodel-
ing (iPLA2β) of membrane lipids. It will be of interest to analyze
mitochondria from patients with mutations in COASY, that alters
the same metabolic pathway of Pank2, and in C19orf12, that is
linked to the mitochondrial outer membrane and is presumably
connected with lipid metabolism (Hartig et al., 2011). Interest-
ingly enough mitochondrial structure and function perturbations
were found also in cells with defects in type 5 P-type ATPase,
involved in KRS. This could be due to an impairment of lyso-
somal activity and ensuing defects in the clearance of damaged
mitochondria (mitophagy). Perturbations in this process seem to
play a major role in the development of PD, particularly in the
genetic forms linked to mutations in Pink1, DJ-1, and Parkin, and
this could explain the overlap between some forms of NBIA and
PD. Mitochondria are also strategic organelles for the regulation
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of iron metabolism and signiﬁcant connection among iron and
altered membrane structure (Patil et al., 2013) and mitophagy
(Allen et al., 2013) have been described in the literature. In yeast
defects in cardiolipin synthesis lead to diminished formation of
iron–sulfur clusters (ISC) and iron accumulation in the organelles,
a feature often observed in disorders with faulty ISC assembly,
such as Friedreich ataxia or X-linked sideroblastic anemia with
ataxia (XLSA-A; Rouault, 2012). Interestingly mitochondrial iron
overload often brings up cytosolic iron deprivation and a vicious
cycle with increased iron uptake and subsequent deposition in
mitochondria (Huang et al., 2011). Such an iron misdistribution
could be at the same time a strong trigger for the production
of ROS, as occurs in aceruloplasminemia and neuroferritynopa-
thy, and hinder mitochondrial renewal (Allen et al., 2013). The
interplay among membrane homeostasis, mitochondria function-
ing, and iron metabolism may thus play a fundamental role in
the development of different types of NBIA and further inves-
tigation in this ﬁeld should lead to a better understanding of
the biological mechanisms underpinning these neurodegenerative
processes.
ACKNOWLEDGMENT
The ﬁnancial support of Telethon-Italia (grants no. GGP10099
to Sonia Levi and GGP11088 to Sonia Levi and Dario Finazzi) is
gratefully acknowledged.
REFERENCES
Abbruzzese, G., Cossu, G., Balocco, M., Marchese, R., Murgia, D., Melis, M.,
et al. (2011). A pilot trial of deferiprone for neurodegeneration with brain
iron accumulation. Haematologica 96, 1708–1711. doi: 10.3324/haematol.2011.
043018
Ackermann, E. J., Kempner, E. S., and Dennis, E. A. (1994). Ca(2+)-independent
cytosolic phospholipase A2 from macrophage-like P388D1 cells. Isolation and
characterization. J. Biol. Chem. 269, 9227–9233.
Afshar, K., Gönczy, P., DiNardo, S., and Wasserman, S. A. (2001). fumble encodes
a pantothenate kinase homolog required for proper mitosis and meiosis in
Drosophila melanogaster. Genetics 157, 1267–1276.
Alfonso-Pecchio, A., Garcia, M., Leonardi, R., and Jackowski, S. (2012). Compart-
mentalization of mammalian pantothenate kinases. PLoS ONE 7:e49509. doi:
10.1371/journal.pone.0049509
Allen, G. F., Toth, R., James, J., and Ganley, I. G. (2013). Loss of iron trig-
gers PINK1/Parkin-independent mitophagy. EMBO Rep. 14, 1127–1135. doi:
10.1038/embor.2013.168
Arosio, P., andLevi, S. (2010). Cytosolic andmitochondrial ferritins in the regulation
of cellular iron homeostasis and oxidative damage. Biochim. Biophys. Acta 1800,
783–792. doi: 10.1016/j.bbagen.2010.02.005
Balboa, M. A., Pérez, R., and Balsinde, J. (2008). Calcium-independent phospholi-
pase A2 mediates proliferation of human promonocytic U937 cells. FEBS J. 275,
1915–1924. doi: 10.1111/j.1742-4658.2008.06350.x
Balboa, M. A., Varela-Nieto, I., Killermann Lucas, K., and Dennis, E. A. (2002).
Expression and function of phospholipase A(2) in brain. FEBS Lett. 531, 12–17.
doi: 10.1016/S0014-5793(02)03481-6
Balsinde, J., and Dennis, E. A. (1997). Function and inhibition of intracellular
calcium-independent phospholipase A2. J. Biol. Chem. 272, 16069–16072. doi:
10.1074/jbc.272.26.16069
Bao, S., Miller, D. J., Ma, Z., Wohltmann, M., Eng, G., Ramanadham, S., et al.
(2004). Male mice that do not express group VIA phospholipase A2 produce
spermatozoa with impaired motility and have greatly reduced fertility. J. Biol.
Chem. 279, 38194–38200. doi: 10.1074/jbc.M406489200
Baraibar, M. A., Barbeito, A. G., Muhoberac, B. B., and Vidal, R. (2008). Iron-
mediated aggregation and a localized structural change characterize ferritin from
a mutant light chain polypeptide that causes neurodegeneration. J. Biol. Chem.
283, 31679–31689. doi: 10.1074/jbc.M805532200
Baraibar, M. A., Barbeito, A. G., Muhoberac, B. B., and Vidal, R. (2012). A
mutant light-chain ferritin that causes neurodegeneration has enhanced propen-
sity toward oxidative damage. Free Radic. Biol. Med. 52, 1692–1697. doi:
10.1016/j.freeradbiomed.2012.02.015
Baraibar, M. A., Muhoberac, B. B., Garringer, H. J., Hurley, T. D., and Vidal, R.
(2010). Unraveling of the E-helices and disruption of 4-fold pores are associated
with iron mishandling in a mutant ferritin causing neurodegeneration. J. Biol.
Chem. 285, 1950–1956. doi: 10.1074/jbc.M109.042986
Barbeito, A. G., Garringer, H. J., Baraibar, M. A., Gao, X., Arredondo, M., Nunez,
M. T., et al. (2009). Abnormal iron metabolism and oxidative stress in mice
expressing a mutant form of the ferritin light polypeptide gene. J. Neurochem.
109, 1067–1078. doi: 10.1111/j.1471-4159.2009.06028.x
Barbeito, A. G., Levade, T., Delisle, M. B., Ghetti, B., andVidal, R. (2010). Abnormal
iron metabolism in ﬁbroblasts from a patient with the neurodegenerative dis-
ease hereditary ferritinopathy. Mol. Neurodegener. 5:50. doi: 10.1186/1750-1326-
5-50
Beck, G., Sugiura, Y., Shinzawa, K., Kato, S., Setou, M., Tsujimoto, Y., et al.
(2011). Neuroaxonal dystrophy in calcium-independent phospholipase A2β
deﬁciency results from insufﬁcient remodeling and degeneration of mito-
chondrial and presynaptic membranes. J. Neurosci. 31, 11411–11420. doi:
10.1523/JNEUROSCI.0345-11.2011
Behrends, C., Sowa, M. E., Gygi, S. P., and Harper, J. W. (2010). Network organi-
zation of the human autophagy system. Nature 466, 68–76. doi: 10.1038/nature
09204
Bosveld, F., Rana,A., van derWouden, P. E., Lemstra,W., Ritsema,M., Kampinga,H.
H., et al. (2008). De novo CoA biosynthesis is required to maintain DNA integrity
during development of the Drosophila nervous system. Hum. Mol. Genet. 17,
2058–2069. doi: 10.1093/hmg/ddn105
Bras, J.,Verloes,A., Schneider, S.A.,Mole, S. E., andGuerreiro, R. J. (2012). Mutation
of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis. Hum.
Mol. Genet. 21, 2646–2650. doi: 10.1093/hmg/dds089
Brissot, P., Ropert, M., Le Lan, C., and Loreal, O. (2012). Non-transferrin bound
iron: a key role in iron overload and iron toxicity. Biochim. Biophys. Acta 1820,
403–410. doi: 10.1016/j.bbagen.2011.07.014
Brunetti, D., Dusi, S., Giordano, C., Lamperti, C., Morbin, M., Fugnanesi, V., et al.
(2014). Pantethine treatment is effective in recovering the disease phenotype
induced by ketogenic diet in a pantothenate kinase-associated neurodegeneration
mouse model. Brain 137(Pt 1), 57–68. doi: 10.1093/brain/awt325
Brunetti, D., Dusi, S., Morbin, M., Uggetti, A., Moda, F., D’Amato, I., et al. (2012).
Pantothenate kinase-associated neurodegeneration: altered mitochondria mem-
brane potential and defective respiration in Pank2 knock-outmousemodel. Hum.
Mol. Genet. 21, 5294–5305. doi: 10.1093/hmg/dds380
Burke, J. E., and Dennis, E. A. (2009). Phospholipase A2 structure/function,
mechanism, and signaling. J. Lipid Res. 50(Suppl.), S237–S242. doi:
10.1194/jlr.R800033-JLR200
Campanella, A., Privitera, D., Guaraldo, M., Rovelli, E., Barzaghi, C., Gar-
avaglia, B., et al. (2012). Skin ﬁbroblasts from pantothenate kinase-associated
neurodegeneration patients show altered cellular oxidative status and have
defective iron-handling properties. Hum. Mol. Genet. 21, 4049–4059. doi:
10.1093/hmg/dds229
Chinnery, P. F., Crompton, D. E., Birchall, D., Jackson, M. J., Coulthard, A.,
Lombes, A., et al. (2007). Clinical features and natural history of neurofer-
ritinopathy caused by the FTL1 460InsA mutation. Brain 130(Pt 1), 110–119.
doi: 10.1093/brain/awl319
Cowen, D., and Olmstead, E. V. (1963). Infantile neuroaxonal dystrophy. J.
Neuropathol. Exp. Neurol. 22, 175–236.
Cozzi, A., Rovelli, E., Frizzale, G., Campanella, A., Amendola, M., Aro-
sio, P., et al. (2010). Oxidative stress and cell death in cells expressing
L-ferritin variants causing neuroferritinopathy. Neurobiol. Dis. 37, 77–85. doi:
10.1016/j.nbd.2009.09.009
Cozzi, A., Santambrogio, P., Corsi, B., Campanella, A., Arosio, P., and Levi, S. (2006).
Characterization of the L-ferritin variant 460InsA responsible of a hereditary fer-
ritinopathy disorder. Neurobiol. Dis. 23, 644–652. doi: 10.1016/j.nbd.2006.05.004
Crompton, D. E., Chinnery, P. F., Fey, C., Curtis, A. R., Morris, C. M., Kierstan, J.,
et al. (2002). Neuroferritinopathy: a window on the role of iron in neurodegen-
eration. Blood Cells Mol. Dis. 29, 522–531. doi: 10.1006/bcmd.2002.0589
Crompton, D., Rehal, P. K., MacPherson, L., Foster, K., Lunt, P., Hughes, I.,
et al. (2010). Multiplex ligation-dependent probe ampliﬁcation (MLPA) analysis
Frontiers in Pharmacology | Drug Metabolism andTransport May 2014 | Volume 5 | Article 99 | 16
Levi and Finazzi Neurodegeneration with brain iron accumulation
is an effective tool for the detection of novel intragenic PLA2G6 mutations:
implications for molecular diagnosis. Mol. Genet. Metab. 100, 207–212. doi:
10.1016/j.ymgme.2010.02.009
Cui, R., Duan, X. L., Anderson, G. J., Qiao, Y. T., Yu, P., Qian, Z. M., et al.
(2009). Age-dependent expression of hephaestin in the brain of ceruloplasmin-
deﬁcient mice. J. Trace Elem. Med. Biol. 23, 290–299. doi: 10.1016/j.jtemb.2009.
05.004
Curtis, A. R., Fey, C., Morris, C. M., Bindoff, L. A., Ince, P. G., Chinnery, P. F., et al.
(2001). Mutation in the gene encoding ferritin light polypeptide causes dominant
adult-onset basal ganglia disease. Nat. Genet. 28, 350–354. doi: 10.1038/ng571
Dehay, B., Ramirez,A.,Martinez-Vicente,M., Perier, C., Canron,M.H.,Doudnikoff,
E., et al. (2012). Loss of P-typeATPaseATP13A2/PARK9 function induces general
lysosomal deﬁciency and leads to Parkinson disease neurodegeneration. Proc.
Natl. Acad. Sci. U.S.A. 109, 9611–9616. doi: 10.1073/pnas.1112368109
Deng, X., Vidal, R., and Englander, E. W. (2010). Accumulation of oxidative DNA
damage in brain mitochondria in mouse model of hereditary ferritinopathy.
Neurosci. Lett. 479, 44–48. doi: 10.1016/j.neulet.2010.05.025
Devos, D., Moreau, C., Devedjian, J. C., Kluza, J., Petrault, M., Laloux, C., et al.
(2014). Targeting chelatable iron as a therapeutic modality in Parkinson’s disease.
Antioxid. Redox Signal. doi: 10.1089/ars.2013.5593 [Epub ahead of print].
Devos,D., Tchofo, P. J.,Vuillaume, I.,Destée,A., Batey, S., Burn, J., et al. (2009). Clin-
ical features and natural history of neuroferritinopathy caused by the 458dupA
FTL mutation. Brain 132(Pt 6):e109. doi: 10.1093/brain/awn274
Dezortova, M., Herynek, V., Krssak, M., Kronerwetter, C., Trattnig, S., and
Hajek, M. (2012). Two forms of iron as an intrinsic contrast agent in the
basal ganglia of PKAN patients. Contrast Media Mol. Imaging 7, 509–515. doi:
10.1002/cmmi.1482
Dick, K. J., Eckhardt, M., Paisán-Ruiz, C., Alshehhi, A. A., Proukakis, C., Sib-
tain, N. A., et al. (2010). Mutation of FA2H underlies a complicated form of
hereditary spastic paraplegia (SPG35). Hum. Mutat. 31, E1251–E1260. doi:
10.1002/humu.21205
di Patti, M. C., Maio, N., Rizzo, G., De Francesco, G., Persichini, T., Colas-
anti, M., et al. (2009). Dominant mutants of ceruloplasmin impair the copper
loading machinery in aceruloplasminemia. J. Biol. Chem. 284, 4545–4554. doi:
10.1074/jbc.M805688200
Dusek, P.,Dezortova,M., andWuerfel, J. (2013). Imaging of iron. Int. Rev. Neurobiol.
110, 195–239. doi: 10.1016/B978-0-12-410502-7.00010-7
Dusek, P., and Schneider, S. A. (2012). Neurodegeneration with brain iron accumu-
lation. Curr. Opin. Neurol. 25, 499–506. doi: 10.1097/WCO.0b013e3283550cac
Dusek, P., and Schneider, S. A. (2013). Neurodegenerative disorder with brain
iron accumulation previously known as SENDA syndrome now genetically
determined. Mov. Disord. 28, 1051–1052. doi: 10.1002/mds.25424
Dusi, S., Valletta, L., Haack, T. B., Tsuchiya, Y., Venco, P., Pasqualato, S., et al.
(2014). Exome sequence reveals mutations in CoA synthase as a cause of neu-
rodegeneration with brain iron accumulation. Am. J. Hum. Genet. 94, 11–22. doi:
10.1016/j.ajhg.2013.11.008
Edvardson, S., Hama, H., Shaag, A., Gomori, J. M., Berger, I., Soffer, D., et al. (2008).
Mutations in the fatty acid 2-hydroxylase gene are associated with leukodystrophy
with spastic paraparesis and dystonia. Am. J. Hum. Genet. 83, 643–648. doi:
10.1016/j.ajhg.2008.10.010
Engel, L. A., Jing, Z. O’Brien, D. E., Sun, M., and Kotzbauer, P. T. (2010). Catalytic
function of PLA2G6 is impaired by mutations associated with infantile neu-
roaxonal dystrophy but not dystonia-parkinsonism. PLoS ONE 5:e12897. doi:
10.1371/journal.pone.0012897
Farina, L., Nardocci, N., Bruzzone, M. G., D’Incerti, L., Zorzi, G., Verga, L., et al.
(1999). Infantile neuroaxonal dystrophy: neuroradiological studies in 11 patients.
Neuroradiology 41, 376–380.
Finkenstedt, A., Wolf, E., Hofner, E., Gasser, B. I., Bosch, S., Bakry, R., et al.
(2010). Hepatic but not brain iron is rapidly chelated by deferasirox in aceru-
loplasminemia due to a novel gene mutation. J. Hepatol. 53, 1101–1107. doi:
10.1016/j.jhep.2010.04.039
Fischer, A., Sananbenesi, F., Mungenast, A., and Tsai, L. H. (2010). Targeting the
correct HDAC(s) to treat cognitive disorders. Trends Pharmacol. Sci. 31, 605–617.
doi: 10.1016/j.tips.2010.09.003
Forni,G. L., Balocco,M.,Cremonesi, L.,Abbruzzese,G., Parodi, R. C., andMarchese,
R. (2008). Regression of symptoms after selective iron chelation therapy in a case
of neurodegeneration with brain iron accumulation. Mov. Disord. 23, 904–907.
doi: 10.1002/mds.22002
Galvin, J. E., Giasson, B.,Hurtig,H. I., Lee,V.M., andTrojanowski, J. Q. (2000). Neu-
rodegeneration with brain iron accumulation, type 1 is characterized by alpha-,
beta-, and gamma-synuclein neuropathology. Am. J. Pathol. 157, 361–368.
Garcia,M., Leonardi, R., Zhang,Y.M.,Rehg, J. E., and Jackowski, S. (2012). Germline
deletion of pantothenate kinases 1 and 2 reveals the key roles for CoA in postnatal
metabolism. PLoS ONE 7:e40871. doi: 10.1371/journal.pone.0040871
Gonzalez-Cuyar, L. F., Perry, G., Miyajima, H., Atwood, C. S., Riveros-Angel, M.,
Lyons, P. F., et al. (2008). Redox active iron accumulation in aceruloplasminemia.
Neuropathology 28, 466–471. doi: 10.1111/j.1440-1789.2008.00901.x
Green, J. T., Orr, S. K., and Bazinet, R. P. (2008). The emerging role of group VI
calcium-independent phospholipase A2 in releasing docosahexaenoic acid from
brain phospholipids. J. Lipid Res. 49, 939–944. doi: 10.1194/jlr.R700017-JLR200
Gregory, A., and Hayﬂick, S. J. (2011). Genetics of neurodegeneration with
brain iron accumulation. Curr. Neurol. Neurosci. Rep. 11, 254–261. doi:
10.1007/s11910-011-0181-3
Gregory, A., Polster, B. J., and Hayﬂick, S. J. (2009). Clinical and genetic delineation
of neurodegeneration with brain iron accumulation. J. Med. Genet. 46, 73–80.
doi: 10.1136/jmg.2008.061929
Gregory, A., Westaway, S. K., Holm, I. E., Kotzbauer, P. T., Hogarth, P., Sonek, S.,
et al. (2008). Neurodegeneration associated with genetic defects in phospholipase
A(2). Neurology 71, 1402–1409. doi: 10.1212/01.wnl.0000327094.67726.28
Grünewald, A., Arns, B., Seibler, P., Rakovic, A., Münchau, A., Ramirez, A., et al.
(2012). ATP13A2 mutations impair mitochondrial function in ﬁbroblasts from
patients with Kufor–Rakeb syndrome. Neurobiol. Aging 33, 1843.e1–1843.e7. doi:
10.1016/j.neurobiolaging.2011.12.035
Haack, T. B., Hogarth, P., Kruer, M. C., Gregory, A., Wieland, T., Schwarzmayr,
T., et al. (2012). Exome sequencing reveals de novo WDR45 mutations causing a
phenotypically distinct, X-linked dominant form of NBIA. Am. J. Hum. Genet.
91, 1144–1149. doi: 10.1016/j.ajhg.2012.10.019
Hadziahmetovic, M., Dentchev, T., Song, Y., Haddad, N., He, X., Hahn, P.,
et al. (2008). Ceruloplasmin/hephaestin knockout mice model morphologic and
molecular features of AMD. Invest. Ophthalmol. Vis. Sci. 49, 2728–2736. doi:
10.1167/iovs.07-1472
Hadziahmetovic, M., Song, Y., Wolkow, N., Iacovelli, J., Grieco, S., Lee, J.,
et al. (2011). The oral iron chelator deferiprone protects against iron overload-
induced retinal degeneration. Invest. Ophthalmol. Vis. Sci. 52, 959–968. doi:
10.1167/iovs.10-6207
Hahn, P., Qian, Y., Dentchev, T., Chen, L., Beard, J., Harris, Z. L., et al. (2004).
Disruption of ceruloplasmin and hephaestin in mice causes retinal iron overload
and retinal degeneration with features of age-related macular degeneration. Proc.
Natl. Acad. Sci. U.S.A. 101, 13850–13855. doi: 10.1073/pnas.0405146101
Harris, Z. L., Durley, A. P., Man, T. K., and Gitlin, J. D. (1999). Targeted gene
disruption reveals an essential role for ceruloplasmin in cellular iron efﬂux. Proc.
Natl. Acad. Sci. U.S.A. 96, 10812–10817.
Hartig, M. B., Hörtnagel, K., Garavaglia, B., Zorzi, G., Kmiec, T., Klopstock, T., et al.
(2006). Genotypic and phenotypic spectrum of PANK2 mutations in patients
with neurodegeneration with brain iron accumulation. Ann. Neurol. 59, 248–256.
doi: 10.1002/ana.20771
Hartig, M. B., Iuso, A., Haack, T., Kmiec, T., Jurkiewicz, E., Heim, K., et al. (2011).
Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical
subtype of neurodegeneration with brain iron accumulation. Am. J. Hum. Genet.
89, 543–550. doi: 10.1016/j.ajhg.2011.09.007
Hayﬂick, S. J., Kruer,M. C., Gregory,A., Haack, T. B., Kurian,M.A., Houlden,H. H.,
et al. (2013). β-Propeller protein-associated neurodegeneration: a new X-linked
dominant disorder with brain iron accumulation. Brain 136(Pt 6), 1708–1717.
doi: 10.1093/brain/awt095
Hayﬂick, S. J., Westaway, S. K., Levinson, B., Zhou, B., Johnson, M. A., Ching, K.
H., et al. (2003). Genetic, clinical, and radiographic delineation of Hallervorden–
Spatz syndrome. N. Engl. J. Med. 348, 33–40. doi: 10.1056/NEJMoa020817
Hellman,N. E., Kono, S.,Miyajima,H., andGitlin, J. D. (2002). Biochemical analysis
of a missense mutation in aceruloplasminemia. J. Biol. Chem. 277, 1375–1380.
doi: 10.1074/jbc.M109123200
Hogarth, P., Gregory, A., Kruer, M. C., Sanford, L., Wagoner, W., Natowicz, M. R.,
et al. (2013). New NBIA subtype: genetic, clinical, pathologic, and radiographic
features of MPAN.Neurology 80, 268–275. doi: 10.1212/WNL.0b013e31827e07be
Hooks, S. B., and Cummings, B. S. (2008). Role of Ca2+-independent phospholi-
pase A2 in cell growth and signaling. Biochem. Pharmacol. 76, 1059–1067. doi:
10.1016/j.bcp.2008.07.044
www.frontiersin.org May 2014 | Volume 5 | Article 99 | 17
Levi and Finazzi Neurodegeneration with brain iron accumulation
Hörtnagel, K., Prokisch, H., and Meitinger, T. (2003). An isoform of hPANK2,
deﬁcient in pantothenate kinase-associated neurodegeneration, localizes to
mitochondria. Hum. Mol. Genet. 12, 321–327.
Huang, M. L., Lane, D. J., and Richardson. D. R. (2011). Mitochondrial mayhem:
the mitochondrion as a modulator of iron metabolism and its role in disease.
Antioxid. Redox. Signal. 15, 3003–3019. doi: 10.1089/ars.2011.3921
Itoh, K., Negishi, H., Obayashi, C., Hayashi, Y., Hanioka, K., Imai, Y., et al. (1993).
Infantile neuroaxonal dystrophy – immunohistochemical and ultrastructural
studies on the central and peripheral nervous systems in infantile neuroaxonal
dystrophy. Kobe J. Med. Sci. 39, 133–146.
Iuso, A., Sibon, O. C., Gorza, M., Heim, K., Organisti, C., Meitinger, T., et al.
(2014). Impairment of Drosophila orthologs of the human orphan protein
C19orf12 induces bang sensitivity and neurodegeneration. PLoS ONE 9:e89439.
doi: 10.1371/journal.pone.0089439
Jeong, S. Y., and David, S. (2003). Glycosylphosphatidylinositol-anchored cerulo-
plasmin is required for iron efﬂux from cells in the central nervous system. J. Biol.
Chem. 278, 27144–27148. doi: 10.1074/jbc.M301988200
Jeong, S. Y., and David, S. (2006). Age-related changes in iron homeostasis and
cell death in the cerebellum of ceruloplasmin-deﬁcient mice. J. Neurosci. 26,
9810–9819. doi: 10.1523/JNEUROSCI.2922-06.2006
Johnson, M. A., Kuo, Y. M.,Westaway, S. K., Parker, S. M., Ching, K. H., Gitschier, J.,
et al. (2004). Mitochondrial localization of human PANK2 and hypotheses of sec-
ondary iron accumulation in pantothenate kinase-associated neurodegeneration.
Ann. N. Y. Acad. Sci. 1012, 282–298. doi: 10.1196/annals.1306.023
Kaneko, K., Hineno, A., Yoshida, K., Ohara, S., Morita, H., and Ikeda,
S. (2012). Extensive brain pathology in a patient with aceruloplasmine-
mia with a prolonged duration of illness. Hum. Pathol. 43, 451–456. doi:
10.1016/j.humpath.2011.05.016
Kono, S. (2012). Aceruloplasminemia. Curr. Drug Targets 13, 1190–1199.
Kono, S. (2013). Aceruloplasminemia: an update. Int. Rev. Neurobiol. 110, 125–151.
doi: 10.1016/B978-0-12-41-0502-7.00007-7
Kono, S., and Miyajima, H. (2006). Molecular and pathological basis of aceruloplas-
minemia. Biol. Res. 39, 15–23. doi: 10.4067/S0716-97602006000100003
Kono, S., Suzuki, H., Oda, T., Miyajima, H., Takahashi, Y., Shirakawa, K.,
et al. (2006). Biochemical features of ceruloplasmin gene mutations linked to
aceruloplasminemia. Neuromol. Med. 8, 361–374. doi: 10.1385/NMM:8:3:361
Kono, S., Suzuki, H., Oda, T., Shirakawa, K., Takahashi, Y., Kitagawa, M.,
et al. (2007). Cys-881 is essential for the trafﬁcking and secretion of truncated
mutant ceruloplasmin in aceruloplasminemia. J. Hepatol. 47, 844–850. doi:
10.1016/j.jhep.2007.05.013
Kono, S., Yoshida, K., Tomosugi, N., Terada, T., Hamaya, Y., Kanaoka, S.,
et al. (2010). Biological effects of mutant ceruloplasmin on hepcidin-mediated
internalization of ferroportin. Biochim. Biophys. Acta 1802, 968–975. doi:
10.1016/j.bbadis.2010.07.011
Kotzbauer, P. T., Truax, A. C., Trojanowski, J. Q., and Lee, V. M. (2005).
Altered neuronal mitochondrial coenzyme A synthesis in neurodegeneration
with brain iron accumulation caused by abnormal processing, stability, and cat-
alytic activity of mutant pantothenate kinase 2. J. Neurosci. 25, 689–698. doi:
10.1523/JNEUROSCI.4265-04.2005
Kruer, M. C., and Boddaert, N. (2012). Neurodegeneration with brain iron accu-
mulation: a diagnostic algorithm. Semin. Pediatr. Neurol. 19, 67–74. doi:
10.1016/j.spen.2012.04.001
Kruer, M. C., Hiken, M., Gregory, A., Malandrini, A., Clark, D., Hogarth, P.,
et al. (2011). Novel histopathologic ﬁndings in molecularly-conﬁrmed pan-
tothenate kinase-associated neurodegeneration. Brain 134(Pt 4), 947–958. doi:
10.1093/brain/awr042
Kruer,M. C., Paisán-Ruiz, C., Boddaert, N.,Yoon,M.Y.,Hama,H., Gregory,A., et al.
(2010). Defective FA2H leads to a novel form of neurodegeneration with brain
iron accumulation (NBIA). Ann. Neurol. 68, 611–618. doi: 10.1002/ana.22122
Kruer, M. C., Salih, M. A., Mooney, C., Alzahrani, J., Elmalik, S. A., Kabiraj, M. M.,
et al. (2014). C19orf12 mutation leads to a pallido-pyramidal syndrome. Gene
537, 352–356. doi: 10.1016/j.gene.2013.11.039
Kubota,A.,Hida,A., Ichikawa,Y.,Momose,Y., Goto, J., Igeta,Y., et al. (2009). A novel
ferritin light chain gene mutation in a Japanese family with neuroferritinopa-
thy: description of clinical features and implications for genotype-phenotype
correlations. Mov. Disord. 24, 441–445. doi: 10.1002/mds.22435
Kuo, Y. M., Duncan, J. L., Westaway, S. K., Yang, H., Nune, G., Xu, E. Y., et al.
(2005). Deﬁciency of pantothenate kinase 2 (Pank2) in mice leads to retinal
degeneration and azoospermia. Hum. Mol. Genet. 14, 49–57. doi: 10.1093/hmg/
ddi005
Kurian, M. A., and Hayﬂick, S. J. (2013). Pantothenate kinase-associated neurode-
generation (PKAN) and PLA2G6-associated neurodegeneration (PLAN): review
of two major neurodegeneration with brain iron accumulation (NBIA) pheno-
types. Int. Rev. Neurobiol. 110, 49–71. doi: 10.1016/B978-0-12-410502-7.00003-X
Kurian, M. A., Morgan, N. V., MacPherson, L., Foster, K., Peake, D., Gupta,
R., et al. (2008). Phenotypic spectrum of neurodegeneration associated with
mutations in the PLA2G6 gene (PLAN). Neurology 70, 1623–1629. doi:
10.1212/01.wnl.0000310986.48286.8e
Kwiatkowski, A., Ryckewaert, G., Jissendi Tchofo, P., Moreau, C., Vuillaume, I.,
Chinnery, P. F., et al. (2012). Long-term improvement under deferiprone in a case
of neurodegeneration with brain iron accumulation. Parkinsonism Relat. Disord.
18, 110–112. doi: 10.1016/j.parkreldis.2011.06.024
Landouré, G., Zhu, P. P., Lourenço, C. M., Johnson, J. O., Toro, C., Bricceno, K. V.,
et al. (2013). Hereditary spastic paraplegia type 43 (SPG43) is caused by mutation
in C19orf12. Hum. Mutat. 34, 1357–1360. doi: 10.1002/humu.22378
Larsson, P. K., Claesson, H. E., and Kennedy, B. P. (1998). Multiple splice variants of
the human calcium-independent phospholipase A2 and their effect on enzyme
activity. J. Biol. Chem. 273, 207–214. doi: 10.1074/jbc.273.1.207
Lawson, D. M., Artymiuk, P. J., Yewdall, S. J., Smith, J. M., Livingstone, J. C.,
Treffry, A., et al. (1991). Solving the structure of human H ferritin by genet-
ically engineering intermolecular crystal contacts. Nature 349, 541–544. doi:
10.1038/349541a0
Lehn, A., Boyle, R., Brown, H., Airey, C., and Mellick, G. (2012).
Neuroferritinopathy. Parkinsonism Relat. Disord. 18, 909–915. doi:
10.1016/j.parkreldis.2012.06.021
Leonardi, R., Rock, C. O., Jackowski, S., and Zhang, Y. M. (2007a). Activation of
human mitochondrial pantothenate kinase 2 by palmitoylcarnitine. Proc. Natl.
Acad. Sci. U.S.A. 104, 1494–1499. doi: 10.1073/pnas.0607621104
Leonardi, R., Zhang, Y. M., Lykidis, A., Rock, C. O., and Jackowski, S. (2007b).
Localization and regulation of mouse pantothenate kinase 2. FEBS Lett. 581,
4639–4644. doi: 10.1016/j.febslet.2007.08.056
Leonardi, R., Zhang,Y. M., Rock, C. O., and Jackowski, S. (2005). Coenzyme A: back
in action. Prog. Lipid Res. 44, 125–153. doi: 10.1016/j.plipres.2005.04.001
Levi, S., Santambrogio, P., Cozzi, A., Rovida, E., Corsi, B., Tamborini, E., et al.
(1994). The role of the L-chain in ferritin iron incorporation. Studies of homo
and heteropolymers. J. Mol. Biol. 238, 649–654. doi: 10.1006/jmbi.1994.1325
Lu, Q., Yang, P., Huang, X., Hu, W., Guo, B., Wu, F., et al. (2011). The WD40
repeat PtdIns(3)P-binding protein EPG-6 regulates progression of omegasomes
to autophagosomes. Dev. Cell 21, 343–357. doi: 10.1016/j.devcel.2011.06.024
Luscieti, S., Santambrogio, P., Langlois d’Estaintot, B., Granier, T., Cozzi, A., Poli,
M., et al. (2010). Mutant ferritin L-chains that cause neurodegeneration act in a
dominant-negative manner to reduce ferritin iron incorporation. J. Biol. Chem.
285, 11948–11957. doi: 10.1074/jbc.M109.096404
Maciel, P., Cruz, V. T., Constante, M., Iniesta, I., Costa, M. C., Gal-
lati, S., et al. (2005). Neuroferritinopathy: missense mutation in FTL caus-
ing early-onset bilateral pallidal involvement. Neurology 65, 603–605. doi:
10.1212/01.wnl.0000178224.81169.c2
Malik, I., Turk, J., Mancuso, D. J., Montier, L., Wohltmann, M., Wozniak, D. F., et al.
(2008). Disrupted membrane homeostasis and accumulation of ubiquitinated
proteins in a mouse model of infantile neuroaxonal dystrophy caused by PLA2G6
mutations. Am. J. Pathol. 172, 406–416. doi: 10.2353/ajpath.2008.070823
Mancuso, M., Davidzon, G., Kurlan, R. M., Tawil, R., Bonilla, E., Di Mauro, S., et al.
(2005). Hereditary ferritinopathy: a novel mutation, its cellular pathology, and
pathogenetic insights. J. Neuropathol. Exp. Neurol. 64, 280–294.
Mariani, R., Arosio, C., Pelucchi, S., Grisoli, M., Piga, A., Trombini, P., et al. (2004).
Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel
missense mutation. Gut 53, 756–758. doi: 10.1136/gut.2003.030429
McNeill, A., Birchall, D., Hayﬂick, S. J., Gregory, A., Schenk, J. F., Zimmerman,
E. A., et al. (2008). T2* and FSE MRI distinguishes four subtypes of neu-
rodegeneration with brain iron accumulation. Neurology 70, 1614–1619. doi:
10.1212/01.wnl.0000310985.40011.d6
Miyajima,H. (2003). Aceruloplasminemia, an ironmetabolic disorder. Neuropathol-
ogy 23, 345–350. doi: 10.1046/j.1440-1789.2003.00521.x
Miyajima, H., Nishimura,Y., Mizoguchi, K., Sakamoto, M., Shimizu, T., and Honda,
N. (1987). Familial apoceruloplasmin deﬁciency associated with blepharospasm
and retinal degeneration. Neurology 37, 761–767. doi: 10.1212/WNL.37.5.761
Frontiers in Pharmacology | Drug Metabolism andTransport May 2014 | Volume 5 | Article 99 | 18
Levi and Finazzi Neurodegeneration with brain iron accumulation
Morgan, N. V., Westaway, S. K., Morton, J. E., Gregory, A., Gissen, P., Sonek, S., et al.
(2006). PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative
disorders with high brain iron. Nat. Genet. 38, 752–754. doi: 10.1038/ng1826
Morita, H., Ikeda, S., Yamamoto, K., Morita, S., Yoshida, K., Nomoto, S., et al.
(1995). Hereditary ceruloplasmin deﬁciency with hemosiderosis: a clinicopatho-
logical study of a Japanese family. Ann. Neurol. 37, 646–656. doi: 10.1002/ana.
410370515
Muhoberac, B. B., Baraibar, M. A., and Vidal, R. (2011). Iron loading-induced
aggregation and reduction of iron incorporation in heteropolymeric ferritin con-
taining a mutant light chain that causes neurodegeneration. Biochim. Biophys.
Acta 1812, 544–548. doi: 10.1016/j.bbadis.2010.10.010
Neumann, M., Adler, S., Schlüter, O., Kremmer, E., Benecke, R., and Kretzschmar,
H. A. (2000). Alpha-synuclein accumulation in a case of neurodegeneration
with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden–Spatz
syndrome) with widespread cortical and brainstem-type Lewy bodies. Acta
Neuropathol. 100, 568–574.
Ogimoto, M., Anzai, K., Takenoshita, H., Kogawa, K., Akehi, Y., Yoshida, R., et al.
(2011). Criteria for early identiﬁcation of aceruloplasminemia. Intern. Med. 50,
1415–1418. doi: 10.2169/internalmedicine.50.5108
Ohta, E., and Takiyama,Y. (2012). MRI ﬁndings in neuroferritinopathy. Neurol. Res.
Int. 2012, 197438. doi: 10.1155/2012/197438
Ohta, E., Nagasaka, T., Shindo, K., Toma, S., Nagasaka, K., Ohta, K.,
et al. (2008). Neuroferritinopathy in a Japanese family with a duplication
in the ferritin light chain gene. Neurology 70(16 Pt 2), 1493–1494. doi:
10.1212/01.wnl.0000310428.74624.95
Paisán-Ruiz, C., Li, A., Schneider, S. A., Holton, J. L., Johnson, R., Kidd, D., et al.
(2012). Widespread Lewy body and tau accumulation in childhood and adult
onset dystonia-parkinsonism cases with PLA2G6 mutations. Neurobiol. Aging 33,
814–823. doi: 10.1016/j.neurobiolaging.2010.05.009
Pandey, V., Varun, P., Turm, H., Hagit, T., Bekenstein, U., Uriya, B., et al. (2013). A
new in vivo model of pantothenate kinase-associated neurodegeneration reveals
a surprising role for transcriptional regulation in pathogenesis. Front. Cell.
Neurosci. 7:146. doi: 10.3389/fncel.2013.00146
Panteghini, C., Zorzi, G., Venco, P., Dusi, S., Reale, C., Brunetti, D., et al. (2012).
C19orf12 and FA2H mutations are rare in Italian patients with neurodegen-
eration with brain iron accumulation. Semin. Pediatr. Neurol. 19, 75–81. doi:
10.1016/j.spen.2012.03.006
Park, J. S., Koentjoro, B., Veivers, D., Mackay-Sim, A., and Sue, C. M. (2014).
Parkinson’s disease-associated human ATP13A2 (PARK9) deﬁciency causes
zinc dyshomeostasis and mitochondrial dysfunction. Hum. Mol. Genet. doi:
10.1093/hmg/ddt623 [Epub ahead of print].
Patel, B. N., Dunn, R. J., and David, S. (2000). Alternative RNA splicing generates
a glycosylphosphatidylinositol-anchored form of ceruloplasmin in mammalian
brain. J. Biol. Chem. 275, 4305–4310. doi: 10.1074/jbc.275.6.4305
Patel, B. N., Dunn, R. J., Jeong, S. Y., Zhu, Q., Julien, J. P., and David, S. (2002).
Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury.
J. Neurosci. 22, 6578–6586.
Patil, V. A., Fox, J. L., Gohil, V. M., Winge, D. R., and Greenberg, M. L.
(2013). Loss of cardiolipin leads to perturbation of mitochondrial and cellu-
lar iron homeostasis. J. Biol. Chem. 288, 1696–1705. doi: 10.1074/jbc.M112.
428938
Pérez, R., Balboa, M. A., and Balsinde, J. (2006). Involvement of group VIA
calcium-independent phospholipase A2 in macrophage engulfment of hydrogen
peroxide-treated U937 cells. J. Immunol. 176, 2555–2561. doi: 10.4049/jim-
munol.176.4.2555
Perry, T. L., Norman, M. G., Yong, V. W., Whiting, S., Crichton, J. U., Hansen,
S., et al. (1985). Hallervorden–Spatz disease: cysteine accumulation and cysteine
dioxygenase deﬁciency in the globus pallidus. Ann. Neurol. 18, 482–489. doi:
10.1002/ana.410180411
Poli, M., Derosas, M., Luscieti, S., Cavadini, P., Campanella, A., Verardi, R., et al.
(2010). Pantothenate kinase-2 (Pank2) silencing causes cell growth reduction,
cell-speciﬁc ferroportin upregulation and iron deregulation. Neurobiol. Dis. 39,
204–210. doi: 10.1016/j.nbd.2010.04.009
Polster, B. J., Yoon, M. Y., and Hayﬂick, S. J. (2010). Characterization of the human
PANK2 promoter. Gene 465, 53–60. doi: 10.1016/j.gene.2010.06.011
Potter, K. A., Kern, M. J., Fullbright, G., Bielawski, J., Scherer, S. S., Yum, S. W.,
et al. (2011). Central nervous system dysfunction in a mouse model of FA2H
deﬁciency. Glia 59, 1009–1021. doi: 10.1002/glia.21172
Ramonet, D., Podhajska, A., Stafa, K., Sonnay, S., Trancikova, A., Tsika, E., et al.
(2012). PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and
regulates cation homeostasis and neuronal integrity. Hum. Mol. Genet. 21, 1725–
1743. doi: 10.1093/hmg/ddr606
Rana, A., Seinen, E., Siudeja, K., Muntendam, R., Srinivasan, B., van der Want, J.
J., et al. (2010). Pantethine rescues a Drosophila model for pantothenate kinase-
associated neurodegeneration. Proc. Natl. Acad. Sci. U.S.A. 107, 6988–6993. doi:
10.1073/pnas.0912105107
Roberti Mdo, R., Borges Filho, H. M., Goncalves, C. H., and Lima, F. L. (2011).
Aceruloplasminemia: a rare disease – diagnosis and treatment of two cases. Rev.
Bras. Hematol. Hemoter. 33, 389–392. doi: 10.5581/1516-8484.20110104
Rouault, T. A. (2012). Biogenesis of iron–sulfur clusters in mammalian cells: new
insights and relevance to human disease. Dis. Model. Mech. 5, 155–164. doi:
10.1242/dmm.009019
Rouault, T. A. (2013). Iron metabolism in the CNS: implications for neurodegener-
ative diseases. Nat. Rev. Neurosci. 14, 551–564. doi: 10.1038/nrn3453
Saitsu, H., Nishimura, T., Muramatsu, K., Kodera, H., Kumada, S., Sugai, K.,
et al. (2013). De novo mutations in the autophagy gene WDR45 cause static
encephalopathy of childhood with neurodegeneration in adulthood. Nat. Genet.
45, 445–449, 449e1. doi: 10.1038/ng.2562
Santambrogio, P., Levi, S., Cozzi, A., Rovida, E., Albertini, A., and Arosio,
P. (1993). Production and characterization of recombinant heteropolymers of
human ferritin H and L chains. J. Biol. Chem. 268, 12744–12748.
Schneider, S. A., Paisan-Ruiz, C., Quinn, N. P., Lees, A. J., Houlden, H., Hardy, J.,
et al. (2010). ATP13A2 mutations (PARK9) cause neurodegeneration with brain
iron accumulation. Mov. Disord. 25, 979–984. doi: 10.1002/mds.22947
Schneider, S. A., Zorzi, G., and Nardocci, N. (2013). Pathophysiology and treatment
of neurodegeneration with brain iron accumulation in the pediatric population.
Curr. Treat. Options Neurol. 15, 652–667. doi: 10.1007/s11940-013-0254-5
Schultheis, P. J., Fleming, S. M., Clippinger, A. K., Lewis, J., Tsunemi, T., Giasson, B.,
et al. (2013). Atp13a2-deﬁcient mice exhibit neuronal ceroid lipofuscinosis, lim-
ited α-synuclein accumulation and age-dependent sensorimotor deﬁcits. Hum.
Mol. Genet. 22, 2067–2082. doi: 10.1093/hmg/ddt057
Schulz, K., Vulpe, C. D., Harris, L. Z., and David, S. (2011). Iron efﬂux from
oligodendrocytes is differentially regulated in gray and white matter. J. Neurosci.
31, 13301–13311. doi: 10.1523/JNEUROSCI.2838-11.2011
Seleznev, K., Zhao, C., Zhang, X. H., Song, K., and Ma, Z. A. (2006). Calcium-
independent phospholipase A2 localizes in and protects mitochondria during
apoptotic induction by staurosporine. J. Biol. Chem. 281, 22275–22288. doi:
10.1074/jbc.M604330200
Sethi, K. D., Adams, R. J., Loring, D. W., and el Gammal, T. (1988). Hallervorden–
Spatz syndrome: clinical and magnetic resonance imaging correlations. Ann.
Neurol. 24, 692–694. doi: 10.1002/ana.410240519
Shinzawa, K., Sumi,H., Ikawa,M.,Matsuoka,Y., Okabe,M., Sakoda, S., et al. (2008).
Neuroaxonal dystrophy caused by group VIA phospholipase A2 deﬁciency in
mice: a model of human neurodegenerative disease. J. Neurosci. 28, 2212–2220.
doi: 10.1523/JNEUROSCI.4354-07.2008
Shinzawa, K., and Tsujimoto, Y. (2003). PLA2 activity is required for nuclear
shrinkage in caspase-independent cell death. J. Cell Biol. 163, 1219–1230. doi:
10.1083/jcb.200306159
Siudeja, K., Grzeschik, N. A., Rana, A., de Jong, J., and Sibon, O. C. (2012).
Coﬁlin/twinstar phosphorylation levels increase in response to impaired coen-
zyme a metabolism. PLoS ONE 7:e43145. doi: 10.1371/journal.pone.0043145
Siudeja, K., Srinivasan, B., Xu, L., Rana, A., de Jong, J., Nollen, E. A.,
et al. (2011). Impaired coenzyme A metabolism affects histone and tubulin
acetylation in Drosophila and human cell models of pantothenate kinase asso-
ciated neurodegeneration. EMBO Mol. Med. 3, 755–766. doi: 10.1002/emmm.
201100180
Skidmore, F. M., Drago, V., Foster, P., Schmalfuss, I. M., Heilman, K. M., and
Streiff, R. R. (2008). Aceruloplasminaemiawith progressive atrophywithout brain
iron overload: treatment with oral chelation. J. Neurol. Neurosurg. Psychiatry 79,
467–470. doi: 10.1136/jnnp.2007.120568
Smani, T., Zakharov, S. I., Csutora, P., Leno, E., Trepakova, E. S., and Bolotina, V. M.
(2004). A novel mechanism for the store-operated calcium inﬂux pathway. Nat.
Cell Biol. 6, 113–120. doi: 10.1038/ncb1089
Storti, E., Cortese, F., Di Fabio, R., Fiorillo, C., Pierallini, A., Tessa, A., et al. (2013).
De novo FTL mutation: a clinical, neuroimaging, and molecular study. Mov.
Disord. 28, 252–253. doi: 10.1002/mds.25275
www.frontiersin.org May 2014 | Volume 5 | Article 99 | 19
Levi and Finazzi Neurodegeneration with brain iron accumulation
Strokin, M., Seburn, K. L., Cox, G. A., Martens, K. A., and Reiser, G. (2012). Severe
disturbance in the Ca2+ signaling in astrocytes from mouse models of human
infantile neuroaxonal dystrophy with mutated Pla2g6. Hum. Mol. Genet. 21,
2807–2814. doi: 10.1093/hmg/dds108
Tahiliani, A. G., and Neely, J. R. (1987). Mitochondrial synthesis of coenzyme A is
on the external surface. J. Mol. Cell. Cardiol. 19, 1161–1167. doi: 10.1016/S0022-
2828(87)80526-6
Tan, J., Zhang, T., Jiang, L., Chi, J., Hu, D., Pan, Q., et al. (2011). Regulation of intra-
cellular manganese homeostasis by Kufor–Rakeb syndrome-associated ATP13A2
protein. J. Biol. Chem. 286, 29654–29662. doi: 10.1074/jbc.M111.233874
Tang, J., Kriz, R. W., Wolfman, N., Shaffer, M., Seehra, J., and Jones, S. S. (1997).
A novel cytosolic calcium-independent phospholipase A2 contains eight ankyrin
motifs. J. Biol. Chem. 272, 8567–8575. doi: 10.1074/jbc.272.13.8567
Texel, S. J., Camandola, S., Ladenheim, B., Rothman, S. M., Mughal, M. R., Unger,
E. L., et al. (2012). Ceruloplasmin deﬁciency results in an anxiety phenotype
involving deﬁcits in hippocampal iron, serotonin, and BDNF. J. Neurochem. 120,
125–134. doi: 10.1111/j.1471-4159.2011.07554.x
Tsunemi, T., and Krainc, D. (2013). Zn2+ dyshomeostasis caused by loss of
ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumula-
tion. Hum Mol. Genet. doi: 10.1093/hmg/ddt572 [Epub ahead of print].
Usenovic, M., Tresse, E., Mazzulli, J. R., Taylor, J. P., and Krainc, D. (2012). Deﬁ-
ciency of ATP13A2 leads to lysosomal dysfunction, α-synuclein accumulation,
and neurotoxicity. J. Neurosci. 32, 4240–4246. doi: 10.1523/JNEUROSCI.5575-
11.2012
Vidal, R., Ghetti, B., Takao, M., Brefel-Courbon, C., Uro-Coste, E., Glazier, B.
S., et al. (2004). Intracellular ferritin accumulation in neural and extraneu-
ral tissue characterizes a neurodegenerative disease associated with a muta-
tion in the ferritin light polypeptide gene. J. Neuropathol. Exp. Neurol. 63,
363–380.
Vidal, R., Miravalle, L., Gao, X., Barbeito, A. G., Baraibar, M. A., Hekmatyar, S. K.,
et al. (2008). Expression of a mutant form of the ferritin light chain gene induces
neurodegeneration and iron overload in transgenic mice. J. Neurosci. 28, 60–67.
doi: 10.1523/JNEUROSCI.3962-07.2008
Wada, H., Yasuda, T., Miura, I., Watabe, K., Sawa, C., Kamijuku, H., et al. (2009).
Establishment of an improved mouse model for infantile neuroaxonal dystrophy
that shows early disease onset and bears a point mutation in Pla2g6. Am. J. Pathol.
175, 2257–2263. doi: 10.2353/ajpath.2009.090343
Wakabayashi, K., Fukushima, T., Koide, R., Horikawa, Y., Hasegawa, M.,
Watanabe, Y., et al. (2000). Juvenile-onset generalized neuroaxonal dys-
trophy (Hallervorden–Spatz disease) with diffuse neuroﬁbrillary and Lewy
body pathology. Acta Neuropathol. 99, 331–336. doi: 10.1007/s004010
050049
Wang, J., Jiang, H., and Xie, J. X. (2007). Ferroportin1 and hephaestin are involved
in the nigral iron accumulation of 6-OHDA-lesioned rats. Eur. J. Neurosci. 25,
2766–2772. doi: 10.1111/j.1460-9568.2007.05515.x
Williams, S. D., and Gottlieb, R. A. (2002). Inhibition of mitochondrial calcium-
independent phospholipase A2 (iPLA2) attenuates mitochondrial phospholipid
loss and is cardioprotective. Biochem. J. 362(Pt 1), 23–32. doi: 10.1042/0264-
6021:3620023
Wills, A. J., Sawle, G. V., Guilbert, P. R., and Curtis, A. R. (2002). Palatal tremor
and cognitive decline in neuroferritinopathy. J. Neurol. Neurosurg. Psychiatry 73,
91–92. doi: 10.1136/jnnp.73.1.91
Winstead, M. V., Balsinde, J., and Dennis, E. A. (2000). Calcium-independent phos-
pholipase A(2): structure and function. Biochim. Biophys. Acta 1488, 28–39. doi:
10.1016/S1388-1981(00)00107-4
Wolkow, N., Song, D., Song, Y., Chu, S., Hadziahmetovic, M., Lee, J. C., et al. (2012).
Ferroxidase hephaestin’s cell-autonomous role in the retinal pigment epithelium.
Am. J. Pathol. 180, 1614–1624. doi: 10.1016/j.ajpath.2011.12.041
Wu, Y., Jiang, Y., Gao, Z., Wang, J., Yuan, Y., Xiong, H., et al. (2009a). Clin-
ical study and PLA2G6 mutation screening analysis in Chinese patients with
infantile neuroaxonal dystrophy. Eur. J. Neurol. 16, 240–245. doi: 10.1111/j.1468-
1331.2008.02397.x
Wu, Z., Li, C., Lv, S., and Zhou, B. (2009b). Pantothenate kinase-associated neurode-
generation: insights from a Drosophila model. Hum. Mol. Genet. 18, 3659–3672.
doi: 10.1093/hmg/ddp314
Yamamoto, K., Yoshida, K., Miyagoe, Y., Ishikawa, A., Hanaoka, K., Nomoto, S.,
et al. (2002). Quantitative evaluation of expression of iron-metabolism genes
in ceruloplasmin-deﬁcient mice. Biochim. Biophys. Acta 1588, 195–202. doi:
10.1016/S0925-4439(02)00165-5
Yang, H. C., Mosior, M., Johnson, C. A., Chen, Y., and Dennis, E. A. (1999). Group-
speciﬁc assays that distinguish between the four major types of mammalian
phospholipase A2. Anal. Biochem. 269, 278–288. doi: 10.1006/abio.1999.4053
Yoshida, K., Furihata, K., Takeda, S., Nakamura, A., Yamamoto, K., Morita, H.,
et al. (1995). A mutation in the ceruloplasmin gene is associated with systemic
hemosiderosis in humans. Nat. Genet. 9, 267–272. doi: 10.1038/ng0395-267
Zhang, X. H., Zhao, C., Seleznev, K., Song, K., Manfredi, J. J., and Ma, Z. A.
(2006a). Disruption of G1-phase phospholipid turnover by inhibition of Ca2+-
independent phospholipase A2 induces a p53-dependent cell-cycle arrest in G1
phase. J. Cell Sci. 119(Pt 6), 1005–1015. doi: 10.1242/jcs.02821
Zhang, Y. M., Rock, C. O., and Jackowski, S. (2006b). Biochemical properties of
human pantothenate kinase 2 isoforms and mutations linked to pantothen-
ate kinase-associated neurodegeneration. J. Biol. Chem. 281, 107–114. doi:
10.1074/jbc.M508825200
Zhou, B.,Westaway, S. K., Levinson, B., Johnson, M. A., Gitschier, J., and Hayﬂick, S.
J. (2001). Anovel pantothenate kinase gene (PANK2) is defective inHallervorden–
Spatz syndrome. Nat. Genet. 28, 345–349. doi: 10.1038/ng572
Zhyvoloup, A., Nemazanyy, I., Babich, A., Panasyuk, G., Pobigailo, N., Vud-
maska, M., et al. (2002). Molecular cloning of CoA synthase. The missing link
in CoA biosynthesis. J. Biol. Chem. 277, 22107–22110. doi: 10.1074/jbc.C200
195200
Zöller, I., Meixner, M., Hartmann, D., Büssow, H., Meyer, R., Gieselmann, V.,
et al. (2008). Absence of 2-hydroxylated sphingolipids is compatible with normal
neural development but causes late-onset axon and myelin sheath degeneration.
J. Neurosci. 28, 9741–9754. doi: 10.1523/JNEUROSCI.0458-08.2008
Zorzi, G., Zibordi, F., Chiapparini, L., Bertini, E., Russo, L., Piga, A., et al. (2011).
Iron-related MRI images in patients with pantothenate kinase-associated neu-
rodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial.
Mov. Disord. 26, 1756–1759. doi: 10.1002/mds.23751
Conflict of Interest Statement:The authors declare that the researchwas conducted
in the absence of any commercial or ﬁnancial relationships that could be construed
as a potential conﬂict of interest.
Received: 28 February 2014; paper pending published: 24 March 2014; accepted: 17
April 2014; published online: 07 May 2014.
Citation: Levi S and Finazzi D (2014) Neurodegeneration with brain iron accumula-
tion: update on pathogenic mechanisms. Front. Pharmacol. 5:99. doi: 10.3389/fphar.
2014.00099
This article was submitted to Drug Metabolism and Transport, a section of the journal
Frontiers in Pharmacology.
Copyright © 2014 Levi and Finazzi. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
Frontiers in Pharmacology | Drug Metabolism andTransport May 2014 | Volume 5 | Article 99 | 20
